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RESUMO 
 
O poliomavírus neurotrópico humano JC (vírus JC) infeta de forma persistente e subclínica o 
trato gastrointestinal e urinário de cerca de 60-80% da população adulta mundial e é conhecido como o 
agente etiológico da Leucoencefalopatia Multifocal Progressiva em indivíduos imunocomprometidos. 
Recentemente, diversos estudos documentaram a deteção do genoma do vírus JC em amostras de 
tumores humanos quer de origem neural quer de origem não neural. De facto, sequências nucleotídicas 
do vírus JC e respetivas proteínas virais têm sido detetadas em diversas neoplasias humanas, incluindo 
no cancro colorretal. A oncogenicidade do vírus JC parece estar associada com a atividade da 
oncoproteína antigénio-T grande nas células hospedeiras. O antigénio-T do vírus JC tem a capacidade 
de desregular o controlo do ciclo celular, interagindo com proteínas supressoras de tumor, como a p53 
e a pRb, o que o torna impar na capacidade de simultaneamente comprometer a integridade 
cromossómica e inativar os pontos de controlo do ciclo celular. Adicionalmente, o antigénio-T tende a 
autoperpetuar-se nas células infetadas e a imortalizar as transformadas, mediante interação com 
diversas outras proteínas celulares, tais como a IRS-1 e a beta-catenina. 
Não estando ainda estabelecida uma relação causa-efeito direta, são necessários estudos 
adicionais, sistematizados e bem concebidos, com o intuito de esclarecer o papel do vírus JC no 
desenvolvimento de cancro colorretal, na medida em que poderá ser um alvo de estratégias preventivas 
e terapêuticas na oncogénese colorretal. 
 
Atendendo ao facto de que o cancro colorretal apresenta uma elevada taxa de incidência na 
população Portuguesa, sendo a primeira causa de morte por neoplasia maligna, e que não foram, até à 
data, relatados estudos nesta matéria, o presente trabalho teve como principal objetivo esclarecer o 
papel que o vírus JC poderá desempenhar no desenvolvimento do cancro colorretal na população 
Portuguesa. Neste sentido, procedeu-se à avaliação: a) da frequência da infeção por vírus JC na 
mucosa colorretal, quer normal quer hiperplásica (pólipos), displásica (adenomas) e neoplásica 
(adenocarcinomas), e concomitante eliminação do vírus através da urina, numa população adulta 
Portuguesa padrão, b) da potencial associação entre a presença do vírus no cólon e o desenvolvimento, 
a gravidade e o grau das lesões colorretais, utilizando um painel de lesões com diferentes graus de 
hiperplasia/displasia/neoplasia, e c) do estado mutacional do gene TP53, de forma a rastrear potenciais 
alterações genéticas que possam atuar como co-fatores de risco na carcinogénese colorectal mediada 
pelo vírus JC em indivíduos infetados. 
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Foram estudadas amostras de mucosa colorretal e de urina de 100 doentes (grupo de estudo) e 
de 100 indivíduos controlo (grupo controlo) com indicação para realização de biópsia ou cirurgia 
colorretal para diagnóstico/tratamento de patologias colorretais. A seleção dos indivíduos a incluir no 
grupo de estudo e no grupo controlo foi efetuada durante os procedimentos colonoscópicos e mediante 
a presença ou ausência de lesões colorretais. 
A deteção das sequências de DNA da estirpe Mad-1 do vírus JC foi efetuada por Nested-PCR, 
em DNA genómico obtido a partir das amostras de mucosa colorretal e de urina de ambos os grupos, 
utilizando dois conjuntos de primers complementares à sequência do gene viral que codifica a proteína 
antigénio-t pequeno. O rastreio mutacional do gene TP53 foi realizado por PCR seguida de 
Sequenciação Direta, utilizando DNA genómico obtido das amostras de mucosa colorrectal, quer 
normal quer displásica/neoplásica, de indivíduos infetados e não infetados pelo vírus JC. 
 
A presente abordagem experimental permitiu a deteção de sequências de DNA do vírus JC 
(JCV+) em 169 dos 200 indivíduos estudados (84,5%). O DNA viral estava presente em 90 dos 100 
doentes (90%) com lesões colorretais: em 23 de 26 (89%) pólipos hiperplásicos, 39 de 42 (93%) 
adenomas tubulares, 7 de 7 (100%) adenomas vilosos, 9 de 11 (82%) adenomas túbulo-vilosos e 12 de 
14 (86%) adenocarcinomas. Neste grupo, sequências de DNA viral foram também detetadas em 48 das 
100 (48%) amostras de mucosa normal adjacente, todas elas contíguas a lesões positivas para a 
presença do vírus, e em 41 de 100 (41%) amostras de mucosa normal não-adjacente. Em 60 das 100 
(60%) amostras de mucosa normal dos indivíduos do grupo de controlo não foi detetado DNA viral 
(JCV-). Identificaram-se ainda sequências de DNA do vírus em 39 das 90 (43%) amostras de urina 
colhidas, sem diferenças estatisticamente significativas entre as estimativas de risco calculadas para a 
eliminação do vírus pela urina em ambos os grupos (48% para o grupo de estudo e 37% para o grupo 
controlo). 
 
Num total de 81 amostras de mucosa colorretal normal infetadas pelo vírus JC, de 40 controlos 
e 41 doentes, a análise mutacional do gene TP53 permitiu a deteção de cinco alterações genéticas 
distintas (11818insC Int2, 11827G> C Int2, 11875insC Int2, 13399A> G EX6 e 19037insC Ex11, esta 
última ainda não descrita até à data) em 10 dos 40 controlos (25%) e 30 dos 41 doentes (73%). Nas 
119 amostras de mucosa colorretal normal, negativas para a presença de DNA viral (60 controlos e 59 
doentes), foi possível a deteção de uma única alteração no gene TP53 (11875insC Int2) em 5 dos 60 
controlos (8%) e 13 dos 59 doentes (22%). Além disso, 74 amostras de mucosa colorretal 
displásica/neoplásica, 60 adenomas (55 JCV+ e 5 JCV-) e 14 adenocarcinomas (12 JCV+ e 2 JCV-), 
foram rastreadas para variantes do gene TP53 e quatro alterações genéticas concomitantes foram 
encontradas (11827G>C Int2, 12139C>G Ex4, 13399A>G Ex6 e a 19037insC Ex11) em todas as 
amostras estudadas. 
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Os resultados do presente estudo parecem refletir uma condição em que as células 
transformadas do epitélio colorretal oferecem um ambiente mais permissivo à replicação do vírus JC, 
sendo a infeção efetiva mesmo nos estadios mais precoces, como por exemplo nos pólipos 
hiperplásicos. O vírus JC parece apresentar um tropismo específico pelas células epiteliais com algum 
tipo de predisposição prévia e propensas a transformação oncogénica, parecendo haver seleção clonal 
das células infetadas. 
Além disso, este estudo permitiu revelar a extensão epidemiológica da infeção pelo vírus JC, 
no trato gastrointestinal e urinário de uma população Portuguesa normal, e considerar a ocorrência de 
uma seleção biológica, das células infetadas pelo vírus, durante a tumorigénese em indivíduos com 
lesões colorretais. 
Adicionalmente observou-se que as alterações genéticas mais relevantes encontradas no gene 
TP53, tais como o novo polimorfismo identificado na região 3 '-UTR (19037insC Ex11) e a variante 
do codão 72 (12139C> G Ex4), são uma característica comum e exclusiva das células do epitélio 
colorretal de indivíduos infetados pelo vírus JC, especialmente aqueles com história clínica de 
displasia/neoplasia. Estas variantes do gene da p53 poderão, de alguma forma, estar relacionadas com 
a mudança do risco de desenvolvimento de cancro colorretal na presença do vírus JC. No entanto, a 
sua implicação no processo de carcinogénese colorretal mediada pelo vírus requer esclarecimentos 
adicionais. 
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ABSTRACT 
 
The human neurotropic polyomavirus JC (JCV) infects, persistent- and sub-clinically, the 
gastrointestinal and urinary tract of 60-80% of the world adult population and causes Progressive 
Multifocal Leukoencephalopathy in immuno-compromised patients. Recently, a number of reports 
have documented the detection of JCV genome in samples derived from several types of neural and 
non-neural human tumours. In fact JCV DNA sequences and proteins have been detected in several 
human cancers, including in colorectal cancer (CRC), and its oncogenicity depends on viral large T-
antigen oncoprotein (T-Ag) activity in human cells. JCV T-Ag can deregulate control of the cell cycle 
by interacting with the tumour suppressor proteins p53 and pRb, making it unique in the ability to 
simultaneously disrupt chromosomal integrity and inactivate cell cycle checkpoints. Additionally, it 
tends to self perpetuate within infected cells and to immortalize the transformed ones, cooperatively 
with a broad range of other cellular proteins, such as IRS-1 and beta-catenin. 
Since there is not a direct cause-effect relationship, systematic and well-designed studies are 
necessary to clarify the role of JCV in colorectal cancer, particularly because it can be the target of 
preventive measures for this type of cancer. 
 
Attending the fact that CRC has a high incidence rate in the Portuguese population, being the 
first leading cause of death by cancer, and that no data have been reported on this matter, this research 
work aimed to clarify whether JCV might have a potential role in the colorectal cancer development in 
the Portuguese population. Thus, we assessed: a) the frequency of the JCV infection in the colorectal 
mucosa, either normal or with hyperplastic (polyps), dysplastic (adenomas) or neoplastic 
(adenocarcinomas) colonic lesions, and the viral shedding through urine, in a standard adult 
Portuguese population; b) the potential association between the presence of the virus in the colon and 
the lesions development, severity and grade, using a panel of lesions with different grades of 
hyperplasia/dysplasia/neoplasia; and c) the mutational status of the TP53 gene in order to evaluate 
genetic alterations that might act as risk modifiers in JCV-mediated colorectal carcinogenesis in 
infected individuals. 
 
We studied the colorectal mucosa and urine of 100 patients (study group) and 100 healthy 
individuals (control group) with indication to perform colorectal biopsy or surgery for 
diagnosis/treatment of colorectal disorders. The selection between the study group and control group 
was made during colonoscopic procedures, depending on the presence or absence of colorectal lesions. 
In order to detect JCV Mad-1 strain DNA sequences Nested-PCR was performed in total 
genomic DNA obtained from both normal and abnormal colorectal mucosa and urine from both 
groups, using two primer sets targeted to the viral gene that encodes the small t-antigen. 
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The mutational screening of the TP53 gene was performed by PCR amplification, followed by 
DNA Sequencing, using total genomic DNA obtained from either normal or dysplastic/neoplastic 
colorectal mucosa samples from JCV infected and non-infected individuals. 
 
We were able to detect viral nucleotide sequences in 169 of the 200 studied individuals 
(84.5%). JCV DNA sequences were present (JCV+) in 90 of the 100 patients (90%) with colorectal 
lesions: in 23 of 26 (89%) hyperplastic polyps, 39 of 42 (93%) tubular adenomas, 7 of 7 (100%) 
villous adenomas, 9 of 11 (82%) tubulovillous adenomas and 12 of 14 (86%) adenocarcinomas. JCV 
DNA was also detected in 48 of the 100 (48%) normal adjacent mucosa samples, all of them adjacent 
to positive colorectal lesions, and in 41 of the 100 (41%) normal non-adjacent mucosa samples. No 
viral DNA (JCV-) was detected in 60 of the 100 (60%) normal mucosa samples of the control group. 
We also detected JCV DNA sequences in 39 of the 90 (43%) collected urine samples, with no 
statistically significant differences between estimates of risk of viral shedding in the urine of both 
groups (48% for the study group and 37% for the control group). 
 
In a total of 81 normal colorectal mucosa specimens infected by JC virus, from 40 controls and 
41 patients, the mutational analysis of the TP53 gene allowed the detection of five different genetic 
alterations (11818insC Int2, 11827G>C Int2, 11875insC Int2, 13399A>G Ex6 and a new 19037insC 
Ex11) in 10 of the 40 controls (25%) and 30 of the 41 patients (73%). Furthermore, from the 119 
normal colorectal mucosa samples with no positivity for JCV DNA (60 controls and 59 patients) we 
were able to identify a single TP53 defect (11875insC Int2) in 5 of the 60 controls (8%) and 13 of the 
59 patients (22%). Furthermore, 74 dysplastic/neoplastic colorectal lesions were screened for TP53 
variants, 60 adenomas (55 JCV+ and 5 JCV-) and 14 adenocarcinomas (12 JCV+ and 2JCV-) from 
patients included in the study group, and four concomitant TP53 genetic alterations were found 
(11827G>C Int2, 12139C>G Ex4, 13399A>G Ex6 and 19037insC Ex11) in all the studied samples. 
 
Our observations may reflect a condition where the transformed colorectal epithelial cells offer 
a more permissive environment for JC virus replication, being effective even since the hyperplastic 
polyps not prone to carcinogenesis. JCV may have a specific tropism for epithelial cells with some 
inherent predisposition and prone to oncogenic transformation, with selection of the infected ones. 
Furthermore, we propose the epidemiological extent of the JCV infection in the 
gastrointestinal and urinary tracts of a normal Portuguese population, and the occurrence of a 
biological selection of JCV infected cells during tumourigenesis in individuals with colorectal lesions. 
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Additionally, we propose that the most relevant genetic alterations found in TP53 gene, such 
as the new single nucleotide polymorphism identified in TP53 3’-untranslated region (19037insC 
Ex11) and the codon 72 variant (12139C>G Ex4), are a common and exclusive characteristic of the 
colorectal epithelium cells of JCV infected individuals, especially those with clinical history of 
dysplastic/neoplastic colorectal lesions. These p53 variants can be associated, in some extent, with the 
risk modification of JCV-mediated colorectal cancer development. However, its implication in the 
JCV-mediated colorectal carcinogenesis requires further elucidation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
xxxvi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
 
 
INDEX 
 
1. Tatiana R Coelho, Luís Almeida, Pedro A. Lazo. JC virus in the pathogenesis of 
colorectal cancer, an etiological agent or another component in a multistep process? 
Virology Journal. 2010; 7:4         1 
  1.1. Abstract and Introduction        1 
  1.2. JCV infection in human population       2 
  1.3. The JC virus         2 
1.4. JCV DNA in normal, benign and malignant colorectal lesions   3 
1.5. Multiple effects of JCV large T- antigen in host cells    3 
  1.6. Effects of JCV agnoprotein in host cells      4 
  1.7. Tumor immune microenvironment       4 
  1.8. Additional aspects in JCV associated oncogenesis     4 
  1.9. Roles that JCV can play in colorectal cancer      5 
   Figure 1         5 
  1.10. Outstanding issues and future prospects      5 
  1.11. References         6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS Open Access
JC virus in the pathogenesis of colorectal cancer,
an etiological agent or another component in a
multistep process?
Tatiana R Coelho1, Luis Almeida1, Pedro A Lazo2*
Abstract
JCV infection occurs early in childhood and last throughout life. JCV has been associated to colorectal cancer and
might contribute to the cancer phenotype by several mechanisms. Among JCV proteins, particularly two of them,
large T-antigen and agnoprotein, can interfere with cell cycle control and genomic instability mechanisms, but
other viral proteins might also contribute to the process. Part of viral DNA sequences are detected in carcinoma
lesions, but less frequently in adenomas, and not in the normal surrounding tissue, suggesting they are integrated
in the host cell genome and these integrations have been selected; in addition viral integration can cause a gene,
or chromosomal damage. The inflammatory infiltration caused by a local chronic viral infection in the intestine can
contribute to the selection and expansion of a tumor prone cell in a cytokine rich microenvironment. JCV may not
be the cause of colorectal cancer, but it can be a relevant risk factor and able to facilitate progression at one or
several stages in tumor progression. JCV transient effects might lead to selective expansion of tumor cells. Since
there is not a direct cause and effect relationship, JCV infection may be an alternative to low frequency cancer pre-
disposition genes.
Cancer is a multifactor disease that its progression is
determined by several genetic alterations, which are
most likely sequentially selected for their contribution to
the tumor phenotype [1]. This phenotypic complexity
makes difficult to determine the specific roles for biolo-
gical agents that might be considered carcinogenic, and
even more difficult to determine their causality, or
implication at a particular stage in disease progression.
Among the exogenous agents associated to cancer initia-
tion or progression are chemicals, which are single
molecules with a specific effect; and some infectious
agents, including viruses and bacteria.
Infectious diseases are acquiring relevance as impor-
tant pathogenic elements in human cancer, since almost
one fifth of human cancers are associated with infec-
tious agent, either bacteria or viruses, particularly in the
gastrointestinal tract [2], but do not represent main-
stream oncologic research. The development of several
types of human cancers can be triggered by the
exposure to different infectious agents, viruses or bac-
teria, such as Human Papilloma Virus (HPV) infection
associated to cervical carcinoma [3], hepatitis B virus to
liver carcinoma [4], Epstein-Barr virus to Burkitt lym-
phomas [5], HTVL-1 to ATL [6], Helicobacter pylori to
gastric carcinoma [7] and more recently a human retro-
virus, XMRV, has been associated to sporadic prostate
cancer [8-10]. More recently, it has been reported the
association between the development of lower gastroin-
testinal tract neoplasias and infectious agents [7], such
as between colorectal cancer (CRC) and JCV infection.
JCV is a virus very well adapted to humans, thus its
widespread infection and adaptation to humans compli-
cates the determination of its etiologic contribution to
cancer development, and it has also been associated to
some neurodegenerative diseases [11].
A chronic infection might be a non genetic alternative
to cancer predisposing genes. The mechanistic role of
infectious agents is even more complex, because they
might contribute in several different ways to oncogen-
esis. Infections can also play a role at different stages in
tumor progression, from initiators to promoters of the
process, depending on the phenotypic aspect to which
* Correspondence: plazozbi@usal.es
2Experimental Therapeutics and Translational Oncology Program, Instituto de
Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones
Científicas (CSIC) - Universidad de Salamanca, Spain
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they can contribute and some might be transient or a
consequence of the host response to chronic infection.
Thus, causality of infectious agents in cancer is some-
what more difficult to demonstrate.
The viral contribution to oncogenesis has to be
addressed by determining how the viral life cycle and
the host response, including their alterations, can be
integrated within the multistep process of tumor devel-
opment. Viruses that are well adapted to humans can
participate in oncogenesis process because they have not
undergone a negative evolutionary pressure, since cancer
develops at an age well above the median age of humans
till the twentieth century, However, the benefits of inter-
fering or preventing infectious agents implicated in can-
cer is very large as demonstrated in hepatic, gastric and
cervical carcinomas [2].
Colorectal cancer (CRC) is the third most common
tumor in women and the fourth in man; representing
annually one million new cases worldwide, and more
than 500.000 deaths are caused by this malignant dis-
ease [12]. Most colorectal cancers are sporadic in their
origin and associated to different risk factors, such as a
diet rich in fat and animal protein intake [13].
JCV infection in human population
The extent of the exposure to JCV infection is indirectly
known by seroprevalence rates detected in different
populations throughout the world, ranging from 44 to
90% in the USA, UK, Germany, Brazil and Japan
[7,14,15]; all indicating it is widespread and common.
The infection may occur by fecal contamination and is
usually persistent and sub clinical, but is reactivated
under conditions of immunosuppression, such as in
patients with AIDS, and JCV can also emerge from
latency and become a lytic infection causing progressive
multifocal leukoencephalopathy (PML) [16]. JCV infec-
tion occurs relatively early during childhood and seropo-
sitivity increases with age, and may be as high as 50% by
the age of 10 [17]. Infection appears to occur through
the gastrointestinal tract [18-20], but also it has been
detected in the respiratory tract raising the possibility of
an oral-fecal transmission [21,22]. The detection of anti-
bodies from childhood to adults suggests that these anti-
bodies are unlikely to be protective, however they are a
clear indicator of exposure, probably multiple or sus-
tained, to JCV. The persistence of seropositivity does
not mean that individual patients have an active infec-
tion at the moment, or that harbor viral DNA or latent
virus in some cells. The antibody mediated immune
response is unlikely to be protective, and control of JCV
infection is more probably performed by T-cell
mediated responses, if successful [23]. It would be inter-
esting to determine if tumor-infiltrating lymphocytes
from colon carcinoma can recognize and react with JCV
infected cells.
Alternatively, urinary secretion of JCV has been used
as an alternative detection method. JCV was present in
24% of the samples out of 498 healthy individuals, and
the proportion increased with age [24]. However, in
immunocompromised patients there is a significant
increase in JCV viruria, although it does not correspond
with the level of immunosuppression, suggesting the
presence of a subclinical infection that might require
additional factors to be reactivated [25]. These data indi-
cate that most people have been exposed for some time
to this virus in order to generate an immune reaction.
In cancer patients viruria was detected in up to 70 per-
cent of the cases, but viral DNA could not be detected
in carcinoma tissue; but this apparent discrepancy might
have a methodological explanation, as primer selection
may not be suitable in case of partial loss of viral DNA,
or viruses might transiently contribute to a particular
stage of tumor progression [14]; particularly since later
several studies were able to detect viral DNA in carci-
noma samples [15,26].
The JC virus
The polyomaviruses family comprises SV40, JCV and
BKV viruses, the primate SV40 virus is the reference
member, while BKV and JCV are much poorly charac-
terized, and mostly done with SV40 specific cross-reac-
tive reagents [27]. Despite their isolation from humans,
their role in human pathology is far from clear for both
JCV and BKV. JCV is a nonenveloped virus with dou-
ble-stranded DNA that forms minichromosomes with
cellular histones. The JCV early region encodes two
oncoproteins, large T antigen (T-Ag) and small t (t-Ag)
antigen and the late region encodes three capsid pro-
teins (VP1, VP2 and VP3) and a small regulatory protein
(Agnoprotein). The viral DNA is packed as a non-envel-
oped virus in a virion composed of 72 pentamers of the
major VP1 capsid protein, that also includes one unit of
the minor VP2 and VP3 proteins [11]. These early viral
proteins have a high transformation and oncogenic
potential in experimental systems [28,29]. There are two
possible outcomes to JCV infection: permissive cells, as
oligodendrocytes, are able to support viral DNA replica-
tion resulting in a lytic infection; in nonpermissive cells,
as those of the colorectal epithelium, resulting in silent
or abortive infection, or probably in cell transformation
and cancer [28]. Despite these evidences, the role of
JCV in human malignancies, and of its oncoproteins in
promoting transformation of cells in vitro and in vivo, is
still far from clear. JCV does not infect experimental
animals, and its roles have been implied by analogy to
SV40 [30].
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JCV is a human neurotropic polyomavirus, and neuro-
logical diseases, such as progressive multifocal leukoence-
phalopathy have been associated to JC virus [11,31].
Initial studies suggested that the transforming ability of
JCV was limited to specific neural cell types, and that this
property mapped to the noncoding regulatory sequence
in the origin of DNA replication, but no neural tumor
has been associated to JCV. However, JCV can also infect
and transform different cell-types in culture and is highly
oncogenic in several laboratory animal models [32].
Furthermore, there is evidence for the presence of the
JCV genome in a broad range of human cell types and
tissues. For example, the JCV genome has been detected
in tonsillar stromal cells, B lymphoid cells, kidney epithe-
lial cells, and upper and lower parts of the gastrointest-
inal tract, including the mucosa of the colon, which is
considered as the natural human reservoir [18].
In addition, the JCV genome has variant forms which
might behave differently from an oncogenic point of view.
The Mad-1 strain, which lacks 98 nucleotides repeats in
its transcriptional regulatory region, was the only one
detected in colon carcinomas from California patients
[33], but no functional study on the characteristics of this
regulatory region has been performed. More recently in
another study performed in Taiwan, most CRC cases
appeared to have the JCV-CY genotype [15], which is also
the dominant genotype in this population, although the
Mad-1 strain was also detected [15]. Thus it is not clear if
this strain association reflects the viral types circulating in
different geographical areas, or if there are particular
strains more strongly associated to carcinomas.
JCV DNA in normal, benign and malignant
colorectal lesions
JCV DNA sequences and proteins have been detected in
a broad range of human tumors of glial and non-glial
origin, including gliomas, ependymomas and medullo-
blastomas, as well as in several non-neural clinical speci-
mens of upper and lower gastrointestinal tumors, such
as colorectal cancer (CRC) [7], suggesting they can
infect a wide range of cell types, but the role of JCV in
human malignancies is still unclear. A very important
issue is to determine whether the presence of JCV pre-
sents any difference between tumor of different grades
and its normal surrounding mucosa. Very few studies
have been performed in this context, but a picture of
the situation is emerging from three independent studies
in Japan [26], Taiwan [15] and South Korea [34]. Rem-
nant JCV large- T DNA was detected in 28-80% of the
cases, but protein was only detected in 16% of the carci-
nomas. Also the frequency is lower in benign adenomas,
and negative in normal surrounding tissue [26]. DNA
corresponding to agnoprotein and VP genes was not
detected suggesting they were deleted [34]. More
importantly in this study no viral DNA sequences were
detected in the adjacent normal tissues [34]. The general
findings are consistent among these three studies, and
the variation in frequency is likely to be a consequence
of the different primers used for viral DNA detection.
However, a similar and earlier study in the USA was not
consistent with this observation, but in that case there
was no microdissection of the CRC biopsies and primers
were different [14]. In none of these studies there is any
indication about the JCV strain implicated.
The variability in JCV detection suggests that in an
infected colon, in some cells there might be integration
with partial loss of JCV DNA, which may have a patho-
genic role in cancer development, probably permitting
additional events that will lead to cancer progression by
permitting selection of a cell subpopulation. When
human CRC samples were grown as xenographs in nude
mice that permit expansion of the cancer cell popula-
tion, all of them resulted positive for JCV [18], suggest-
ing that the cell subpopulation containing JCV might be
selected for its growth and adaptation characteristics. In
a way, this situation is reminiscent of what occurs in
cervical carcinoma, in which most HPV infections and
lesions regress, but some progress, and cervical carcino-
mas have remnant viral DNA coding for some viral pro-
teins, E6 and E7, but the other HPV proteins are not
expressed in these carcinomas [3]; these viral proteins
participate in the oncogenic process, but clearly need
additional, non virally related events [35,36].
Multiple effects of JCV large T- antigen in host
cells
JCV is able to translate its early proteins, namely LT-Ag,
in order to trigger the progression of the cell cycle to
the phase S in host-cell [29,37]. JCV LT-Ag has the abil-
ity to interact with p53; thus it is possible that in some
cells this interference with p53 [38], which also inter-
feres with viral replication [38], might allow the occur-
rence of additional genetic damage representing a step
forward in colon carcinogenesis [39,40]. In addition,
there are several additional mechanisms by which LT-
Ag can also interfere with cellular functions. JCV LT-Ag
can interact with proteins involved in cellular regulation
such as IRS-1 (Insulin receptor substrate-1), a major
protein of the insulin-like growth factor I receptor (IGF-
IR) signaling pathway, which is activated and translo-
cated to the nucleus in the presence of LT-Ag [41].
Activated IRS1, is an adaptor in the cell response to
insulin, activating PI3K, implicated in cell survival [42],
and proliferation signals [43]. Thus at the same time it
will permit survival and expansion of a JCV containing
subpopulation. Some polymorphisms of the IRS1 gene
have been associated with an increased risk of colorectal
cancer [44]. These signaling effects associated to LT-Ag
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can participate at any given stage of cancer progression,
facilitating the expansion of a specific subpopulation,
perhaps already pretumoral. LT-Ag can also inhibit
homologous recombination directed DNA repair (HRR)
causing DNA damage, mechanistically by its interaction
with IRS1 [45], which also interacts with Rad51 at loca-
tions of damaged DNA [46,47], and thus may contribute
to generate some genetic instability in cells containing
JCV [48]. JCV also by a hit and run mechanism, that is
a transient effect, is able to trigger genetic instability by
interacting with p53 and b-catenin in colonic cells,
which is detected only in the first seven days after infec-
tion [49]. LT-Ag also contributes to the stabilization of
b-catenin by a novel mechanism mediated by the small
GTPase Rac1 [50]. b-catenin is an integral component
of the Wnt signaling pathway whose stabilization is
associated with increased transcription of genes that
regulate cellular proliferation, e.g., c-myc and cyclin D1,
despite the fact that the functional consequence of this
JCV interaction in cancer development remains to be
elucidated. LT-Ag interacts with b-catenin [51], and b-
catenin implication in colorectal cancer is well known
[52,53]. This observation is supported by reports on the
involvement of Wnt signaling pathway [54] and c-myc
[55] in colorectal carcinogenesis. If the effect persists for
some time in infected cells harboring JCV, they might
contribute to expand a cell subpopulation that later
might give rise to cancer.
Effects of JCV agnoprotein in host cells
JCV expresses a small 71 aminoacids protein, known as
agnoprotein, which is a regulatory protein that can
repress the expression of p21WAF-1/Cip1, a regulator
of the cell cycle that inhibits the activation of cyclin/
CDK complexes and releases E2F transcription factor
from phospho-Rb, thus agnoprotein removes an inhibi-
tor of cell cycle progression. Consequently, p21WAF-1/
Cip1 and E2F stimulate several proteins, the function of
which is essential for cell cycle progression and rapid
cell proliferation [56]. This role is in some aspects remi-
niscent of the action of E6 in cervical carcinogenesis,
where the elimination of p53 also results in lack of
induction of p21 [57,58], and permits cell cycle progres-
sion. Agnoprotein can also alter the expression of Ku70
and Ku80 [56], two proteins implicated in DNA repair
[59,60], and thus indirectly contribute to a potential
accumulation of genetic damage. Furthermore, agnopro-
tein can also interact with the YB-1 transcription factor
[61], a factor that when is downregulated results in an
induction of apoptosis [62] by regulating the mTOR/Akt
pathway [63]. This YB-1 transcription factor can also
modulate the response to the erbB2 receptor [64], and
contribute prevention of premature senescence [65]. In
addition YB-1 also controls some chemokine ligand [66]
and metaloprotease gene expression, such as MMP13
[67], two types of proteins that can have an important
role in carcinogenesis. YB-1 has been shown to have a
predictive value in breast cancer patients identifying
those with a poorer prognosis [68,69]. However, there is
no systematic study of the presence and role of this
viral protein, or of YB-1, at different stages of CRC pro-
gression. Agnoprotein has been shown to inhibit differ-
entiation of oligiodendrocytes [70]; if a similar effect
could be induced in colonic epithelium, it will be an
additional contributing factor towards tumorigenesis.
But a detailed study of agnoprotein presence in biopsies
representing different stages of CCR has not yet been
performed.
Tumor immune microenvironment
Another important component of tumorigenesis is
represented by the tumor microenvironment, where
local cytokines that can play a stimulatory role. These
cytokines may originate either in the tumor itself or in
the local inflammatory infiltrate, and can activate JCV
gene expression by a cis-acting transcription factor,
Egr1; a factor which mostly activates the late promoter,
and affects VP1 expression and viral replication [71].
The expression of this capsid protein can also trigger an
inflammatory and immune reaction, with the corre-
sponding local availability of several additional cyto-
kines. This viral reactivation might also result in viral
production, dissemination, and reinfection of neighbor-
ing cells. This mechanism could be important for main-
tenance or reactivation of a local subclinical infection.
In this context it is important the recent observation
that patients which have undergone liver transplantation
have an increased risk of colorectal cancer due to reacti-
vation of JCV, probably as a result of immunosuppres-
sive treatment [72].
Additional aspects in JCV associated oncogenesis
Another mechanism by which JCV can contribute to
colorectal carcinogenesis might, in some aspects, be
similar to the role of human papillomaviruses (HPV) in
cervical carcinoma [35,36]. Viral DNA integration has
only been partially addressed in cervical cancer asso-
ciated to HPV [73], and the chromosomal location of
viral integration sites coincides with those of fragile
chromosome sites [74], and with translocation break-
points already detected in other types of carcinomas
[36,75], although the cellular genes affected are not
known. If the JCV infection is persistent, then there is a
good probability that JCV DNA might integrate in the
host cell genome, and some of the viral DNA remains
in a manner similar to what occurs with HPV in cervical
carcinoma [74]. JCV DNA integration appears to be a
common observation in CRC when this issue has been
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studied [26]; however its significance has not yet been
properly addressed. This integration, if demonstrated,
can explain why in some cases JCV is not detected. Inte-
grated JCV DNA may be an important and irreversible
component in the pathogenesis of CRC. In that way a
cell population can harbor viral DNA from which some
viral genes can be expressed with an altered regulation.
The penetrance of the remaining viral gene and its level
of expression might condition the risk of developing
cancer. Also other viral genes might be lost, particularly
those of the capsid, thus an immune reaction against
them will not be effective.
Roles that JCV can play in colorectal cancer
The role of JCV in cancer does not fit within a classical
concept of direct relation between cause and effect as it
is for other infectious diseases and neither as a simple
risk factor as applied to chemical or physical carcino-
gens. JCV might participate in different ways in the
pathogenesis of colorectal cancer; both direct and indir-
ect (Figure 1). This situation is a consequence of the
complexity of the mechanisms contributing to cancer
phenotype, which have many different phases, ranging
from initiation, promotion, morphological progression
with different biological characteristics, to tumor main-
tenance and dissemination. Thus, to pinpoint a unique
mechanism of action for a virus represents a very sim-
plistic approach to the problem. Some of the effects
induced by JCV might be transitory and contribute to
tumor progression at a particular stage of tumor pro-
gression. For example, a transitory genetic instability
will permit generation of generic damage that might
facilitate progression, but once it occurs, it is no longer
needed. Other contributing factors are viral protein
expression or viral DNA integration that might be
important only at some steps in cancer progression.
Also chronic infection is known to be a bad prognostic
indicator due to the immune cell infiltration and genera-
tion of a microenvironment very rich in cytokines,
which can promote expansion of premalignant or malig-
nant cells, not necessarily with JCV, that will facilitate
cancer cell growth and dissemination. Some of the
effects might be transient and this will further compli-
cate establishing a direct relation between JCV and
CRC. In any case there is no evidence, epidemiological
or physiopathological, to rule out a role for JCV in col-
orectal carcinogenesis, even if its role is still undefined;
but on the contrary there is enough information point-
ing to roles that remain to be conclusively established.
Outstanding issues and future prospects
The role of any virus as a causal agent in cancer should
not be considered simply as a direct cause-effect. The
virus should be considered as a complex agent with
potentially multiple and varying effects. In order to
properly establish if JCV is indeed an important risk
Figure 1 Multistep colorectal carcinogenesis. Diagram illustrating the different components by which JCV can participate in multistep
colorectal oncogenesis, either in a transient or irreversible way.
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factor for colorectal cancer there are several issues that
need to be properly addressed.
1. Establish conclusively that CRC patients, in a signif-
icant number of cases, have been exposed to this virus,
and of which an indirect marker will be the presence of
specific antibodies.
2. Improve detection of viral DNA by using standar-
dized sets of primers for each of the relevant viral genes,
as well as strain identification. This should also contri-
bute to establish the potential and irreversible integra-
tion of remnant JCV DNA in cancer cells, and permit
identification of significant differences among malignant,
benign or normal surrounding tissue.
3. Correlate JCV DNA presence with other mutations
known to sequentially occur in CRC, and its association
with other known risk factors.
4. Identification of viral protein expression at different
stages of colorectal cancer progression. For this aim
development of better specific antibodies for JCV pro-
teins are necessary.
5. Characterize the host immune response to JCV in
order to manipulate it and develop strategies to eradi-
cate the virus from the human population. In particular
determine the role T-cell responses, since the natural
antibody response does not seem to be protective.
Acknowledgements
Funded by grants from CSIC (Spain) and Fundaçao para Ciência e a
Tecnologia (Portugal).
Author details
1Instituto de Farmacologia e Terapêutica, Faculdade de Medicina,
Universidade de Coimbra, Portugal. 2Experimental Therapeutics and
Translational Oncology Program, Instituto de Biología Molecular y Celular del
Cáncer, Consejo Superior de Investigaciones Científicas (CSIC) - Universidad
de Salamanca, Spain.
Authors’ contributions
TRC, LA and PAL conceived the study, and participated in its design and
coordination. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 January 2010
Accepted: 18 February 2010 Published: 18 February 2010
References
1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
2. Parkin DM: The global health burden of infection-associated cancers in
the year 2002. Int J Cancer 2006, 118:3030-3044.
3. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical
application. Nature Rev Cancer 2002, 2:342-350.
4. Blumberg BS, London WT: Hepatitis B virus and the prevention of
primary cancer of the liver. J Natl Cancer Inst 1985, 74:267-273.
5. Kuppers R: The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009,
9:15-27.
6. Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1)
infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280.
7. Burnett-Hartman AN, Newcomb PA, Potter JD: Infectious agents and
colorectal cancer: a review of Helicobacter pylori, Streptococcus bovis,
JC virus, and human papillomavirus. Cancer Epidemiol Biomarkers Prev
2008, 17:2970-2979.
8. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K,
Magi-Galluzzi C, Tubbs RR, Ganem D, et al: Identification of a novel
Gammaretrovirus in prostate tumors of patients homozygous for R462Q
RNASEL variant. PLoS Pathog 2006, 2:e25.
9. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D,
Derisi JL, Chow SA, Silverman RH: An infectious retrovirus susceptible to
an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci
USA 2007, 104:1655-1660.
10. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M,
Schlomm T: Prevalence of human gammaretrovirus XMRV in sporadic
prostate cancer. J Clin Virol 2008, 43:277-283.
11. Jiang M, Abend JR, Johnson SF, Imperiale MJ: The role of polyomaviruses
in human disease. Virology 2009, 384:266-273.
12. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74-108.
13. Bingham S, Riboli E: Diet and cancer–the European Prospective
Investigation into Cancer and Nutrition. Nat Rev Cancer 2004, 4:206-215.
14. Newcomb PA, Bush AC, Stoner GL, Lampe JW, Potter JD, Bigler J: No
evidence of an association of JC virus and colon neoplasia. Cancer
Epidemiol Biomarkers Prev 2004, 13:662-666.
15. Lin PY, Fung CY, Chang FP, Huang WS, Chen WC, Wang JY, Chang D:
Prevalence and genotype identification of human JC virus in colon
cancer in Taiwan. J Med Virol 2008, 80:1828-1834.
16. Khalili K, Del Valle L, Otte J, Weaver M, Gordon J: Human neurotropic
polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003,
22:5181-5191.
17. Knowles WA: Discovery and epidemiology of the human polyomaviruses
BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006, 577:19-45.
18. Laghi L, Randolph AE, Chauhan DP, Marra G, Major EO, Neel JV, Boland CR:
JC virus DNA is present in the mucosa of the human colon and in
colorectal cancers. Proc Natl Acad Sci USA 1999, 96:7484-7489.
19. Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE,
Boland CR: JC virus DNA sequences are frequently present in the human
upper and lower gastrointestinal tract. Gastroenterology 2000,
119:1228-1235.
20. Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R:
Potential transmission of human polyomaviruses through the
gastrointestinal tract after exposure to virions or viral DNA. J Virol 2001,
75:10290-10299.
21. Babakir-Mina M, Ciccozzi M, Alteri C, Polchi P, Picardi A, Greco F, Lucarelli G,
Arcese W, Perno CF, Ciotti M: Excretion of the novel polyomaviruses KI
and WU in the stool of patients with hematological disorders. J Med Virol
2009, 81:1668-1673.
22. Sharp CP, Norja P, Anthony I, Bell JE, Simmonds P: Reactivation and
mutation of newly discovered WU, KI, and Merkel cell carcinoma
polyomaviruses in immunosuppressed individuals. J Infect Dis 2009,
199:398-404.
23. Gasnault J, Kahraman M, de Goer de Herve MG, Durali D, Delfraissy JF,
Taoufik Y: Critical role of JC virus-specific CD4 T-cell responses in
preventing progressive multifocal leukoencephalopathy. Aids 2003,
17:1443-1449.
24. Rodrigues C, Pinto D, Medeiros R: Molecular epidemiology
characterization of the urinary excretion of polyomavirus in healthy
individuals from Portugal–a Southern European population. J Med Virol
2007, 79:1194-1198.
25. Doerries K: Human polyomavirus JC and BK persistent infection. Adv Exp
Med Biol 2006, 577:102-116.
26. Hori R, Murai Y, Tsuneyama K, Abdel-Aziz HO, Nomoto K, Takahashi H,
Cheng CM, Kuchina T, Harman BV, Takano Y: Detection of JC virus DNA
sequences in colorectal cancers in Japan. Virchows Arch 2005,
447:723-730.
27. White MK, Khalili K: Polyomaviruses and human cancer: molecular
mechanisms underlying patterns of tumorigenesis. Virology 2004,
324:1-16.
28. Haggerty S, Walker DL, Frisque RJ: JC virus-simian virus 40 genomes
containing heterologous regulatory signals and chimeric early regions:
identification of regions restricting transformation by JC virus. J Virol
1989, 63:2180-2190.
Coelho et al. Virology Journal 2010, 7:42
http://www.virologyj.com/content/7/1/42
Page 6 of 8
29. Khalili K, Sariyer IK, Safak M: Small tumor antigen of polyomaviruses: role
in viral life cycle and cell transformation. J Cell Physiol 2008, 215:309-319.
30. Maginnis MS, Atwood WJ: JC virus: an oncogenic virus in animals and
humans?. Semin Cancer Biol 2009, 19:261-269.
31. Khalili K, Gordon J, White MK: The polyomavirus, JCV and its involvement
in human disease. Adv Exp Med Biol 2006, 577:274-287.
32. Gordon J, Krynska B, Otte J, Houff SA, Khalili K: Oncogenic potential of
human neurotropic papovavirus, JCV, in CNS. Dev Biol Stand 1998,
94:93-101.
33. Ricciardiello L, Chang DK, Laghi L, Goel A, Chang CL, Boland CR: Mad-1 Is
the Exclusive JC Virus Strain Present in the Human Colon, and Its
Transcriptional Control Region Has a Deleted 98-Base-Pair Sequence in
Colon Cancer Tissues. J Virol 2001, 75:1996-2001.
34. Jung WT, Li MS, Goel A, Boland CR: JC virus T-antigen expression in
sporadic adenomatous polyps of the colon. Cancer 2008, 112:1028-1036.
35. Lazo PA: Human papillomaviruses in oncogenesis. Bio Essays 1988,
9:158-162.
36. Lazo PA: The molecular genetics of cervical carcinoma. Br J Cancer 1999,
80:2008-2018.
37. Krynska B, Gordon J, Otte J, Franks R, Knobler R, DeLuca A, Giordano A,
Khalili K: Role of cell cycle regulators in tumor formation in transgenic
mice expressing the human neurotropic virus, JCV, early protein. J Cell
Biochem 1997, 67:223-230.
38. Staib C, Pesch J, Gerwig R, Gerber JK, Brehm U, Stangl A, Grummt F: p53
inhibits JC virus DNA replication in vivo and interacts with JC virus large
T-antigen. Virology 1996, 219:237-246.
39. Niv Y, Goel A, Boland CR: JC virus and colorectal cancer: a possible
trigger in the chromosomal instability pathways. Curr Opin Gastroenterol
2005, 21:85-89.
40. Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS,
Ogino S: JC virus T-antigen in colorectal cancer is associated with p53
expression and chromosomal instability, independent of CpG island
methylator phenotype. Neoplasia 2009, 11:87-95.
41. Khalili K, Del Valle L, Wang JY, Darbinian N, Lassak A, Safak M, Reiss K: T-
antigen of human polyomavirus JC cooperates withIGF-IR signaling
system in cerebellar tumors of the childhood-medulloblastomas.
Anticancer Res 2003, 23:2035-2041.
42. del Rincon SV, Rousseau C, Samanta R, Miller WH Jr: Retinoic acid-induced
growth arrest of MCF-7 cells involves the selective regulation of the IRS-
1/PI 3-kinase/AKT pathway. Oncogene 2003, 22:3353-3360.
43. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV: Oncogenic transformation
by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and
IRS-2. Cell Cycle 2007, 6:705-713.
44. Pechlivanis S, Pardini B, Bermejo JL, Wagner K, Naccarati A, Vodickova L,
Novotny J, Hemminki K, Vodicka P, Forsti A: Insulin pathway related genes
and risk of colorectal cancer: INSR promoter polymorphism shows a
protective effect. Endocr Relat Cancer 2007, 14:733-740.
45. Yu Y, Alwine JC: Interaction between simian virus 40 large T antigen and
insulin receptor substrate 1 is disrupted by the K1 mutation, resulting in
the loss of large T antigen-mediated phosphorylation of Akt. J Virol 2008,
82:4521-4526.
46. Trojanek J, Croul S, Ho T, Wang JY, Darbinyan A, Nowicki M, Del Valle L,
Skorski T, Khalili K, Reiss K: T-antigen of the human polyomavirus JC
attenuates faithful DNA repair by forcing nuclear interaction between
IRS-1 and Rad51. J Cell Physiol 2006, 206:35-46.
47. Trojanek J, Ho T, Croul S, Wang JY, Chintapalli J, Koptyra M, Giordano A,
Khalili K, Reiss K: IRS-1-Rad51 nuclear interaction sensitizes JCV T-antigen
positive medulloblastoma cells to genotoxic treatment. Int J Cancer 2006,
119:539-548.
48. Reiss K, Khalili K, Giordano A, Trojanek J: JC virus large T-antigen and IGF-I
signaling system merge to affect DNA repair and genomic integrity. J
Cell Physiol 2006, 206:295-300.
49. Ricciardiello L, Baglioni M, Giovannini C, Pariali M, Cenacchi G, Ripalti A,
Landini MP, Sawa H, Nagashima K, Frisque RJ, et al: Induction of
chromosomal instability in colonic cells by the human polyomavirus JC
virus. Cancer Res 2003, 63:7256-7262.
50. Bhattacharyya R, Noch EK, Khalili K: A novel role of Rac1 GTPase in JCV T-
antigen-mediated beta-catenin stabilization. Oncogene 2007,
26:7628-7636.
51. Enam S, Del Valle L, Lara C, Gan DD, Ortiz-Hidalgo C, Palazzo JP, Khalili K:
Association of human polyomavirus JCV with colon cancer: evidence for
interaction of viral T-antigen and beta-catenin. Cancer Res 2002,
62:7093-7101.
52. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW:
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science 1997, 275:1787-1790.
53. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW,
Vogelstein B, Clevers H: Constitutive transcriptional activation by a beta-
catenin-Tcf complex in APC-/- colon carcinoma. Science 1997,
275:1784-1787.
54. de Lau W, Barker N, Clevers H: WNT signaling in the normal intestine and
colorectal cancer. Front Biosci 2007, 12:471-491.
55. Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C,
Aranes MJ, Augenlicht LH: c-Myc overexpression sensitises colon cancer
cells to camptothecin-induced apoptosis. Br J Cancer 2003, 89:1757-1765.
56. Darbinyan A, Siddiqui KM, Slonina D, Darbinian N, Amini S, White MK,
Khalili K: Role of JC Virus Agnoprotein in DNA Repair. J Virol 2004,
78:8593-8600.
57. Giannoudis A, Herrington CS: Differential expression of p53 and p21 in
low grade cervical squamous intraepithelial lesions infected with low,
intermediate, and high risk human papillomaviruses. Cancer 2000,
89:1300-1307.
58. Jiang M, Milner J: Selective silencing of viral gene expression in HPV-
positive human cervical carcinoma cells treated with siRNA, a primer of
RNA interference. Oncogene 2002, 21:6041-6048.
59. Celli GB, Denchi EL, de Lange T: Ku70 stimulates fusion of dysfunctional
telomeres yet protects chromosome ends from homologous
recombination. Nat Cell Biol 2006, 8:885-890.
60. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O: Three-dimensional
structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on
DNA and its implications for DNA DSB repair. Mol Cell 2006, 22:511-519.
61. Safak M, Sadowska B, Barrucco R, Khalili K: Functional interaction between
JC virus late regulatory agnoprotein and cellular Y-box binding
transcription factor, YB-1. J Virol 2002, 76:3828-3838.
62. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E,
Kidani A, Hirano G, Masubuchi D, Fukunaka Y, et al: Programmed cell
death protein 4 down-regulates Y-box binding protein-1 expression via
a direct interaction with Twist1 to suppress cancer cell growth. Cancer
Res 2009, 69:3148-3156.
63. Fujii T, Seki N, Namoto-Matsubayashi R, Takahashi H, Inoue Y, Toh U,
Kage M, Shirouzu K: YB-1 prevents apoptosis via the mTOR/STAT3
pathway in HER-2-overexpressing breast cancer cells. Future Oncol 2009,
5:153-156.
64. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM,
Mertens PR, Iftner T, et al: Disruption of the Y-box binding protein-1
results in suppression of the epidermal growth factor receptor and HER-
2. Cancer Res 2006, 66:4872-4879.
65. Lu ZH, Books JT, Ley TJ: YB-1 is important for late-stage embryonic
development, optimal cellular stress responses, and the prevention of
premature senescence. Mol Cell Biol 2005, 25:4625-4637.
66. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, van
Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, Weber C: Y-box binding
protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth
muscle cells and contributes to neointima formation in atherosclerosis-
prone mice. Circulation 2007, 116:1812-1820.
67. Samuel S, Beifuss KK, Bernstein LR: YB-1 binds to the MMP-13 promoter
sequence and represses MMP-13 transactivation via the AP-1 site.
Biochim Biophys Acta 2007, 1769:525-531.
68. Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E, Astanehe A, Hung MC,
Eirew P, Eaves CJ, Dunn SE: Targeting YB-1 in HER-2 overexpressing
breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and
suppresses tumor growth in mice. Cancer Res 2008, 68:8661-8666.
69. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M,
Nielsen TO, Huntsman D, Dunn SE: Redefining prognostic factors for
breast cancer: YB-1 is a stronger predictor of relapse and disease-
specific survival than estrogen receptor or HER-2 across all tumor
subtypes. Breast Cancer Res 2008, 10:R86.
70. Merabova N, Kaniowska D, Kaminski R, Deshmane SL, White MK, Amini S,
Darbinyan A, Khalili K: JC virus agnoprotein inhibits in vitro differentiation
of oligodendrocytes and promotes apoptosis. J Virol 2008, 82:1558-1569.
71. Romagnoli L, Sariyer IK, Tung J, Feliciano M, Sawaya BE, Del Valle L,
Ferrante P, Khalili K, Safak M, White MK: Early growth response-1 protein is
Coelho et al. Virology Journal 2010, 7:42
http://www.virologyj.com/content/7/1/42
Page 7 of 8
induced by JC virus infection and binds and regulates the JC virus
promoter. Virology 2008, 375:331-341.
72. Selgrad M, Koornstra JJ, Fini L, Blom M, Huang R, Devol EB, Boersma-van
Ek W, Dijkstra G, Verdonk RC, de Jong S, et al: JC virus infection in
colorectal neoplasia that develops after liver transplantation. Clin Cancer
Res 2008, 14:6717-6721.
73. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell
control in early events in carcinogenesis. J Natl Cancer Inst 2000,
92:690-698.
74. Popescu NC, DiPaolo JA: Preferential sites for viral integration on
mammalian genome. Cancer GenetCytogenet 1989, 42:157-171.
75. Lazo PA, Gallego MI, Ballester S, Feduchi E: Genetic alterations by human
papillomaviruses in oncogenesis. FEBS Lett 1992, 300:109-113.
doi:10.1186/1743-422X-7-42
Cite this article as: Coelho et al.: JC virus in the pathogenesis of
colorectal cancer, an etiological agent or another component in a
multistep process?. Virology Journal 2010 7:42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Coelho et al. Virology Journal 2010, 7:42
http://www.virologyj.com/content/7/1/42
Page 8 of 8
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
13 
 
INDEX 
 
2. Assessement of human JC polyomavirus presence in normal colorectal mucosa, 
hyperplastic polyps, sporadic adenomas and adenocarcinomas    15 
2.1. Introduction         15 
2.2. Purpose          18 
2.3. Patients and Methods        18 
 2.3.1. Clinical Samples        18 
 2.3.2. Nucleic Acids Extraction       20 
 2.3.3. Detection of JCV DNA Sequences     21 
 2.3.4. Statistical Analysis        22 
2.4. Results          22 
2.5. Discussion          23 
2.6. Conclusions         25 
2.7. Bibliographic References        27 
2.8. Web Site Support         30 
2.9. Figures and Tables         31 
 Figure 2.1         31 
 Table 2.1         32 
Figure 2.2         33 
 Table 2.2         34 
Figure 2.3         35 
 Table 2.3         36 
2.10. Appendix A         37 
2.10.1. Appendix A.I        37 
2.10.2. Appendix A.II        41 
2.10.3. Appendix A.III        45 
2.10.4. Appendix A.IV        61 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
15 
 
CHAPTER 2 
 
2. Assessement of human JC polyomavirus presence in normal colorectal mucosa, hyperplastic 
polyps, sporadic adenomas and adenocarcinomas 
2.1. Introduction 
Infectious diseases are acquiring relevance as important pathogenic elements in tumour 
development, considering that almost one fifth of the human cancers are associated with the presence 
of infectious agents. 
The underlying mechanisms relating the presence of microorganisms and cancer development 
are poorly understood in humans, but it is generally accepted that several types of cancers can be 
triggered by the exposure to different infectious agents, either viruses or bacteria[1,2]. The most 
relevant reports associate the Human Papillomavirus (HPV) with cervical carcinoma[3], Hepatitis B 
Virus (HBV) with liver carcinoma[4], Epstein-Barr Virus (EBV) with Burkitt lymphoma[5], Human 
T-lymphotropic virus 1 (HTLV-1) with adult T-cell leukaemia[6] and Helicobacter pylori with gastric 
carcinoma[7]. However, the role of polyomaviruses, such as Simian Virus 40 (SV40), BK virus 
(BKV) and the human neurotropic polyomavirus JC (JCV), in human cancers has been much more 
controversial. 
 
JCV belongs to the Polyomaviridae family and it is the etiologic agent of the Progressive 
Multifocal Leukoencephalopathy (PML). The name polyoma is derived from the Greek terms: poly-, 
meaning “many”, and -oma, meaning “tumours”, and it refers to the ability of these viruses to cause 
different tumours. JC virus was first isolated in 1971 from the brain of a patient with PML. This virus, 
named Mad-1, is the JCV prototype strain and it has been used in most in vitro and in vivo studies of 
JCV (Diagram 2.1)[8]. 
JCV seems to infect, with rare exceptions, the gastrointestinal and urinary tracts of all human 
populations investigated till date. Most individuals become JC virus-infected during childhood or 
adolescence and, by adulthood, approximately 60–80% is seropositive. Although the exact mechanism 
of JCV transmission is unknown, it is thought to be spread via a fecal–oral route, since the virus can 
be detected in untreated urban sewages, and its presence is prevailing in the gastrointestinal and 
urinary tracts. Initial JCV infection is thought to occur in the tonsils, with posterior spreading to infect 
the epithelium of the kidney, where it establishes a life-long persistent and latent infection (Diagram 
2.2)[9]. 
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Diagram 2.1 - The JC virus (JCV) genome. The JCV genome is small (5.13 kb) and contains a limited coding capacity. 
There is a non-translated regulatory region known as the transcriptional control region (TCR) of about 400 b.p. that contains 
the origin of replication (ori) and the promoters and enhancers that control replication. The early genes (counterclockwise) 
encode two replication proteins, large T-antigen and small t-antigen, which are expressed soon after the virus enters the cell. 
The late region (clockwise) encodes the capsid proteins (VP1, VP2, and VP3) and a maturation protein (agnoprotein), and is 
expressed only after viral DNA replication begins. 
The TCR of the Mad-1 strain of JCV contains two 98 b.p. tandem repeats which contain binding sites for various 
transcription factors. Large T-antigen is not a transcription factor per se but it can auto-regulate the early promoter as the 
replication cycle proceeds. When large T-antigen reaches a sufficient concentration in the cell, it binds to viral DNA which 
may block the assembly of functional transcriptional complexes, repressing early transcription. Large T-antigen indirectly 
contributes to activation of JCV late transcription, perhaps by stabilizing interactions among transcription factors. 
 
 
 
Diagram 2.2 - The JCV life cycle: JCV infection of host cells is initiated by attachment to cellular receptors, α-2,3- or α-2,6-
linked sialic acid and serotonin receptor 5-HT2AR; the virus is internalized into cells by clathrin-dependent endocytosis; JCV 
then traffics through early endosomes and caveosomes to the nucleus; in the nucleus viral early gene transcription occurs, 
followed by viral DNA replication and late gene transcription; after production of the viral structural proteins VP1, VP2, and 
VP3, progeny virions are assembled in the nucleus and released. 
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JCV infection in immuno-competent hosts is usually subclinical and apparently confined to the 
kidney. Still, it remains not clear whether JCV reactivation causes viral spread to the central nervous 
system (CNS) or if a latent infection in the CNS becomes locally reactivated. However, B-
lymphocytes of the bone marrow and peripheral blood are permissive to JCV infection, suggesting that 
viral spread after primary replication may occur via a hematogenous route. In the CNS, JCV infects 
glial cells, including astrocytes and the myelin-producing cells, known as oligodendrocytes[10]. 
In immuno-compromised individuals JCV can become reactivated, leading to an enhanced 
viral replication and to lytic infection of the CNS, causing the destruction of oligodendroglia and 
resulting in the fatal demyelinating disease PML[11,12]. PML has been reported in individuals with 
immuno-suppression caused by human immunodeficiency virus (HIV) infection and acquired 
immunodeficiency syndrome (AIDS)[13], organ transplantation[14] or inherited immuno-deficiencies, 
such as severe combined immunodeficiency (SCID), hyper-immunoglobulinemia M and CD40 ligand 
deficiency. Recently, PML has been reported in patients with Multiple Sclerosis (MS) and Crohn’s 
disease that are receiving the drug natalizumab, which blocks leukocyte transport from the gut to the 
brain[15]. 
 
Although JC virus does not infect hosts other than humans, recent reports state that JCV 
inoculation is able to induce neuronal tumours in experimental animal models. JCV can induce tumour 
formation in small rodents including hamsters[16]and rats[17], and in non-human primates, including 
owl monkeys[18] and squirrel monkeys[19]. The tumour type, origin and characteristics differ 
between host species and also depend on the route of inoculation and virus strain. Although JCV does 
not induce tumours in normal mice, the expression of the viral early region in transgenic mouse 
models can cause tumourigenesis[20]. 
 
The unequivocal oncogenic activity of one of JCV early proteins, the large T-antigen (T-Ag), 
has raised the possibility that JCV can also induce cancer development in human hosts[21]. JCV 
genome (Diagram 2.1) has been detected in several human pre-malignant lesions and in tumours, 
either of neuronal origin, such as medulloblastomas[22], oligoastrocytomas[23] and 
glioblastomas[24], or of non-neuronal origin, particularly in the different stages of colonic 
adenomatous lesions and in colorectal cancer (CRC)[25,26]. In colorectal neoplasias, it has been 
proposed that, under virus activation, the viral regulatory protein coded by T-Ag oncogene is, 
probably, the main key in the carcinogenic mechanism, since it was shown that it is responsible, in a 
carcinogenic multistep pathway, for chromosomal instability (CIN) by disrupting several host-cell 
signalling and regulatory processes[27]. 
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2.2. Purpose 
Even considering the bibliographic lack of consensus, the association between JCV infection 
of the colorectal epithelium cells and the development of CRC is still being suggested, but this 
hypothesis asks for further elucidation, especially at the populational level. 
Colorectal cancer is the third most common cancer in the world. There is an estimative of 1.24 
million of new cases worldwide, per year, and 500.000 deaths caused by this malignant disease. It 
comprises 10% of the global cancer burden and it is the most frequent in Australia, New Zealand, 
Western, Southern and Northern Europe and in North America, being considered as a disease of the 
Western lifestyle[28] 
The wide geographical variation in CRC incidence across the world can be attributed to 
differences in diet, particularly the consumption of red and processed meat, fiber and alcohol, as well 
as bodyweight and physical activity. Incidence rates of CRC are increasing in countries where rates 
were previously low, especially in Japan and other Asian countries, as diets become more 
Westernized, and either gradually stabilizing in Northern and Western Europe or declining in North 
America[28]. 
Colorectal cancer incidence worldwide is noticeably higher in men than in women (rate ratio 
1.4:1.0). In both sexes there are ten-fold differences in incidence between the different regions of the 
world[28]. 
In Portugal, CRC is highly incident, with over six thousand new cases per year, with a 
mortality rate approaching 50% and being the second leading cause of death by cancer, in both 
sexes[29]. Despite these high incidence and mortality rates no studies have been reported, so far, 
stating the JCV oncogenicity or even its occurrence among the Portuguese population. Considering the 
lack of reports on this matter, with this experimental approach we intended to assess: a) the prevalence 
rates of JCV infection in the colorectal mucosa, either normal or with hyperplastic polyps, dysplastic 
(adenomas) or neoplastic (adenocarcinomas) colonic lesions, and the viral shedding through urine, in 
an adult Portuguese population; and b) the potential association between the presence of the virus in 
the colon and the lesions development, severity and grade, using a panel of lesions with different 
grades of hyperplasia/dysplasia/neoplasia. 
 
2.3. Patients and Methods 
2.3.1. Clinical Samples 
All the individuals included in this study were selected exclusively when having medical 
indication to perform colonoscopy and biopsy (diagnostic and/or therapeutic), for evaluation of 
colorectal disorders (Appendix A.I), or surgery for colorectal tumour resection. During the procedure, 
we gathered the relevant clinical data (age, gender, previous clinical history, etc.) from each individual 
selected for the study (Appendix A.II). The harvesting and handling of all clinical samples were 
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performed in the Gastroenterology Department of the Hospitais da Universidade de Coimbra, EPE 
(HUC) and in the Surgery Department of the Centro Hospitalar de Coimbra, EPE (CHC), after 
approval by the respective Ethic Committees and according to its guidelines and protocols (reference 
CES009, 2008 January 17). All patients gave their written informed consent before admission to the 
study (Appendix A.III). 
From 200 volunteers, 830 human clinical specimens were harvested, 740 corresponding to 
colorectal mucosa samples (with approximately 2x2mm), harvested under colonoscopy or surgery, and 
90 corresponding to 20-50ml of urine (Appendix A.IV). 
The selection between the study group and the control group was made during colonoscopy: if 
at least one colorectal hyperplastic/dysplastic/neoplastic lesion was present the individual was 
included in the study group (patients) and if no lesion was found then the individual entered the 
control group (controls). All the individuals submitted to colorectal surgery for tumour resection were 
included in the study group. 
One hundred volunteers were classified as controls (61 males and 59 females), showing no 
clinical history of polyps or oncological colorectal lesions (hyperplastic polyps, adenomas or 
adenocarcinomas). The average age was 63 years±13.37 (23 to 93 years old). Furthermore, one 
hundred patients (67 males and 33 females) were selected for the study group, showing colorectal 
hyperplastic/dysplastic/neoplastic lesions (at least one hyperplastic polyp, adenoma or 
adenocarcinoma) during colonoscopy or surgery, with an average age of 66 years±8.73 (32 to 90 years 
old). 
In the control group (n=100), 2 biopsy sections and 1 urine sample per individual were 
harvested, in a total of 200 biopsy specimens of normal colorectal mucosa and 30 urine samples. From 
70 controls it was not possible to collect urine samples due to non-compliance or physiological 
inability. 
In the study group (n=100), 7 specimens per patient were harvested: a) 2 from hyperplastic 
polyps/adenomas/adenocarcinomas (n=140); b) 2 from each normal colorectal mucosa, both adjacent 
to the lesions (within a perimeter of 5mm) (n=200) and non-adjacent to the lesions (from the proximal 
colon when hyperplastic polyps/adenomas/adenocarcinomas were in the distal colon, and vice-versa) 
(n=200), in a total of 540 colorectal mucosa specimens; and c) 1 urine sample (n=60). From 60 
patients only 1 biopsy sample, corresponding to hyperplastic polyps/adenomas/adenocarcinomas, was 
harvested during colonoscopy due to the small size of the lesions. From 40 patients we were not able 
to collect the urine sample due to specific clinical conditions. 
Each colorectal mucosa sample was preserver in an 1.5ml eppendorf tube with 200µl of 
RNAlater stabilization reagent (Applied, Carlsbad, California) (for posterior studies using RNA), and 
kept at -80ºC. The urine samples were preserved in a 60ml sterilized container and kept at 4-6ºC, until 
experimental procedures. In this study we used only one specimen of each type of the colorectal 
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mucosa samples and a 15ml aliquot of the urine samples from each individual. The remaining 
specimens were preserved at –80ºC for posterior handling. 
The anatomo-pathological diagnosis and staging were carried out in matched pairs of clinical 
samples, sent to the Anatomo-Pathology Departments of HUC and CHC, according to the World 
Health Organization (WHO) Classification of Tumours of the Gastrointestinal Tract. This procedure 
allowed establishing the differential diagnosis of colorectal hyperplastic polyps, tubular, tubulovillous 
and villous adenomas, and adenocarcinomas. 
 
2.3.2. Nucleic Acids Extraction 
Total genomic DNA extraction and purification, from colorectal mucosa specimens kept in 
RNAlater stabilization reagent, was performed by using the InvisorbSpin Tissue Mini Kit (Invitek, 
Berlin, Germany) according to manufacturer’s protocol. 
For total DNA extraction from urine samples we adapted and optimized an experimental 
protocol, previously described by Chang et al[30] for detection of human papillomavirus (HPV) in 
urine samples. Urine samples were homogenized and aliquoted into 15ml falcon tubes and only 10ml 
of each sample were used in this experimental procedure. The samples were centrifuged at 5,500xrpm 
(5444xg), in a refrigerated centrifuge (3-16K, Sigma, Madrid, Spain), at 4°C for 30’. 
After centrifugation, the supernatant was discarded; the pellet was washed with 1ml of sterile 
1× PBS (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4/KH2PO4, pH 7.4) and again centrifuged for 10’. 
In the end, the washing solution was discarded and the pellet re-suspended with 500µl of 1x digestion 
buffer (100mM Tris-HCL, 10mM EDTA, pH 8.0), 50µl of Proteinase K (500µg/ml) (5 Prime, 
Hamburg, Germany) and mixed in the vortex for a few seconds. The solution was then incubated at 
50°C over-night (O/N), for complete digestion, and Proteinase K was finally inactivated at 95°C for 
10’. The cellular debris was precipitated by centrifugation for 5’ and the supernatant was collected in a 
fresh 1.5ml eppendorf tube. 
For total DNA extraction, the samples were then treated according to a 
phenol/chloroform/isoamilic alcohol (25:24:1(v/v/v)) (Applied Biosystems, Weiterstadt, Germany) 
protocol, consisting of successive washes with this solution. We added 500µl to the lysate, gently 
inverted the tube for 2’ and centrifuged the mix at 13000rpm (10000g) for 10’ at room temperature 
(RT). The aqueous supernatant, containing the nucleic acids, was collected in a clean eppendorf tube 
and the same procedure was repeated twice. A final wash with 500µl of chloroform pro-analysis 
(Merck, Darmstadt, Germany) and an additional centrifugation, for 10’, allowed the elimination of 
phenol residues from the nucleic acid solution. 
To retrieve the suspended DNA, we added 50µl of 3M sodium acetate (Merck, Darmstadt, 
Germany), 500µl of 95% ethanol (Merck, Darmstadt, Germany) and centrifuged at 13000 rpm for 30’ 
at RT. After discarding the supernatant, the precipitate was then washed twice with 500µl of 75% 
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ethanol and left to dry O/N at RT. DNA was finally re-suspended with 50µl milli-Q water and stored 
at -20ºC until manipulation. 
Additionally, we evaluated DNA yield and purity by total DNA quantification, in the 
NanoDrop (Termo Scientific, Wilmington, USA), for all the urine and colorectal mucosa samples. The 
urine samples treated with our adapted experimental approach, despite its extended procedure, 
presented higher DNA concentrations, ranging from 10.00 to 78.00ng/µl. 
 
2.3.3. Detection of JCV DNA Sequences 
In order to detect JCV DNA sequences in all the clinical samples, corresponding to colorectal 
mucosa and urine specimens, we performed Nested-PCR with two specifically designed set of primers 
(prepared by StabVida, Caparica, Portugal), complementary to a consensus sequence within the viral 
gene encoding the small t-antigen oncoprotein (t-Ag) of the JCV-Mad-1 strain[31]. 
The first Nested-PCR reaction was carried out with a PCR mixture of 50µl, containing 1× PCR 
incomplete buffer (50mM KCl, 10mM Tris-HCl) (Bioron, Ludwigshafen, Germany), 2mM of Mg2+ 
(Bioron, Ludwigshafen, Germany), 200µM of dNTPs (Bioron, Ludwigshafen, Germany), 20pmol of 
the external primer set (JCTR1F 5’-cttgggttaagtcacaccca-3’ and JCTR2R 5’-atgcaaagaactccaccctg–3’), 
2.5 units of Taq DNA polymerase (Bioron, Ludwigshafen, Germany), 50ng of DNA obtained from 
each clinical sample and Mili-Q water to complete the final volume. The reactions were then 
submitted to thermal cycling: a hot-start (94oC for 10’’), followed by 40 denaturing cycles at 94oC for 
30’’, annealing at 58oC for 30’’ and extension at 72oC for 30’’, with a final extension step at 72oC for 
10’. 
The second Nested-PCR reaction was performed in the same conditions, previously described, 
but using 5µl of the first PCR products as target DNA template, 20pmol of the internal primer set 
(JCTR3F 5’-tccacacaagtgggctgctt-3’ and JCTR4R 5’-ggtggggacgaagacaagat-3’) and an annealing 
temperature of 60ºC. 
In all Nested-PCR amplifications there were both blank and positive controls. As blank 
control, a similar mixture was prepared with no DNA (replaced by the corresponding volume of milli-
Q water) and as positive control we used the plasmid pBR322 – BamHI with the JCV-Mad-1 genome, 
kindly provided by Kamel Khalili MD PhD (Neurovirology and Cancer Biology Department, Temple 
University, Philadelphia – USA). 
Then, 10µl of each Nested-PCR product was resolved by horizontal electrophoresis on 2% 
agarose gels (Bio-Rad, Hercules, California), prepared with 1xTAE (40mM Tris, 20mM acetic acid, 
and 1mM EDTA, pH 8.0), stained with 1:20 (v/v) ethidium bromide (Merck, Germany) and visualized 
under UV light. The JCV DNA sequences size of successfully amplified samples by Nested-PCR was 
identified by comparison with the fragments of a known molecular weight marker, 100 b.p. ladder 
(Bioron, Ludwigshafen, Germany) (Figure 2.1). 
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2.3.4. Statistical Analysis 
Statistical analysis was performed using the Graph-Pad Prism Version 6.0 (GraphPad 
Software, Inc., San Diego, California). Categorical data were analysed with the Chi-Squared or 
Fisher’s Exact Test when appropriated. Differences were considered significant when p<0.05. Results 
are presented in terms of relative frequencies. 
When comparing the study group and the control group, and between samples from each 
group, we have used a rough estimate of risk, the Ratio of Cross-Products or Odds Ratio (OD), with 
intervals for a statistical confidence (CI) of 95%, and the strength of association was performed with 
the Cramer´s Formula. 
 
2.4. Results 
Using the Nested-PCR assay, with our novel primer set targeted to a conserved consensus 
region of the JCV t-Ag gene, we were able to detect viral nucleotide sequences in 169 of the 200 
studied individuals (84.5%). 
In the study group, JCV DNA sequences were present in 90 of the 100 (90%) colorectal 
lesions: in 23 of 26 (89%) hyperplastic polyps, 39 of 42 (93%) tubular adenomas, 7 of 7 (100%) 
villous adenomas, 9 of 11 (82%) tubulovillous adenomas and 12 of 14 (86%) adenocarcinomas (Table 
2.1). JCV DNA sequences were also detected in 48 of the 100 (48%) normal adjacent mucosa 
samples, all of them adjacent to positive colorectal lesions, and in 41 of the 100 (41%) normal non-
adjacent mucosa samples (Figure 2.2A). In this group, the presence of JCV DNA sequences in 
hyperplastic polyps/adenomas/adenocarcinomas was significantly higher compared with the other 
biological specimens (Table 2.2). 
No JCV DNA sequences were detected in 60 of the 100 (60%) normal mucosa samples of the 
control group (Figure 2.2B), and the estimated risk was not significantly different from the 
corresponding colorectal samples of the study group (Figure 2.2C). We also detected JCV DNA 
sequences in 39 of the 90 (43%) collected urine samples, without statistically significant differences 
between estimates of risk of viral shedding in the urine of both groups (Figure 2.2D). The registered 
frequencies were 48% and 37%, for patients and controls, respectively. 
In the study group, if we consider the characteristics of the colorectal lesions, we found that 
the presence of JC virus was significantly higher in adenomas with low-grade of dysplasia, being this 
the predominant grade in the studied patients (Table 2.1). 
Finally, in the control group, all the individuals that showed viral shedding in urine were also 
positive for the viral genome in the normal colorectal mucosa (Figure 2.3A), whereas, in the study 
group, the most common phenotype, considering the viral presence/absence, was that with positivity in 
the colorectal lesion with no JCV DNA sequences in the match pairs of normal mucosa (Figure 2.3B). 
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Furthermore, when there was no positivity in the colorectal lesions, the normal adjacent and non-
adjacent mucosa were also negative (Table 2.3). 
On comparing patients and controls, JCV DNA was preferentially present in hyperplastic 
polyps/adenomas/adenocarcinomas than in normal adjacent (OD 13.58), non-adjacent (OD 9.88) 
mucosa or in urine (OD 9.66). In the study group, the presence of JCV DNA sequences in hyperplastic 
polyps/adenomas/adenocarcinomas is significantly associated (OD 33.67; CI - 1.90-595.21) with its 
presence in one of the matched pairs of normal mucosa or in both. When this estimate of risk is 
transformed in a strength of association, using the Cramer´s formula, we obtain a V=0.94, showing 
that the presence of JCV DNA in colorectal lesions is 94% associated with its presence, at least, in one 
or in both matched pairs of normal mucosa (adjacent and non-adjacent). 
Whenever no viral genome is present in hyperplastic polyps/adenomas/adenocarcinomas, the 
matched pairs of normal adjacent and non-adjacent mucosa were also negative, reinforcing that the 
presence of JCV DNA in colorectal lesions is associated with its presence in any of the normal mucosa 
or in both. 
 
2.5. Discussion 
Despite the high CRC incidence and mortality rates in Portugal[29], this is the first report 
concerning the presence of the JC virus in the gastrointestinal and urinary tracts of a standard adult 
Portuguese population, and a pioneer study on its occurrence in the normal and abnormal colorectal 
mucosa. Generically, in our population sub-set, the prevalence rate for JCV infection does not 
significantly differ from the serological studies stating that JC virus antibodies are detectable in 60-
80% of the world adult populations[32,33]. 
 
Probably, in a geographical, genetic and technically-dependent manner, JCV has been detected 
in the human normal gastrointestinal mucosa (prevalence rates – from 30 to 89%)[27,34,35], 
colorectal adenomas (prevalence rates – from 42 to 88%)[35,36] and in CRC (prevalence rates – from 
61 to 89%)[27,35,37]. Others found JCV nucleotide sequences in 28-80% of adenocarcinoma lesions, 
but less frequently in benign adenomas and not in the normal surrounding tissue, even in the normal 
adjacent colorectal mucosa[36,38,39]. On excluding the results for the normal colorectal mucosa, our 
findings for adenomas, adenocarcinomas and urine (Figure 2.2) are quite similar to the highest 
prevalence rates described in the previously referred reports. 
 
Considering the published data for the different stages of colorectal lesions[34], we found 
comparable relative frequencies of JCV DNA sequences in hyperplastic polyps, tubular adenomas, 
villous adenomas, tubulovillous adenomas and CRC (Table 2.1). The higher presence of JCV DNA in 
colorectal lesions versus normal mucosa, either adjacent or non-adjacent, cannot be explained by 
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occurring through blood contamination, since we assured that colorectal samples harvesting was 
cautiously performed in the apical/distal portion of the lesions. Instead, we assume that the high 
prevalence of JVC DNA sequences in colorectal lesions may be due to a cellular environment prone to 
viral replication and that it is not related with the viral carcinogenic potential, since the presence in 
hyperplastic polyps is quite similar to the presence in adenomas. In fact, our data suggest that JCV 
presence may be closely associated with the lesion itself rather than with its type, grade or severity. On 
the other hand, the absence or scarcity of the virus does not necessarily preclude its potential role in 
host-cell transformation, because it can be silenced or its genome can be lost during tumour 
progression (“hit-and-run” transformation)[40]. 
 
On the contrary, some authors were not able to demonstrate the JCV association with 
colorectal lesions: Hernández Losa et al[41] failed to detect the viral sequences by Nested-PCR, using 
a set of primers that amplified a conserved region within the viral gene that encodes the large T-
antigen, and they were unable to stain the T-Ag protein, by immuno-histochemistry, either in colon 
adenocarcinomas or in the normal colorectal mucosa. They highlighted that, probably, the 
epidemiology of polyomaviruses in the United States should be different from the one in Europe. 
However, our results, and those from similar experimental approaches[35], differ from these 
observations of Losa and colleagues, possibly due to the set of primers we designed, targeted to a 
consensus sequence within the viral gene that encodes the small t-antigen (t-Ag) oncoprotein of the 
JCV Mad-1 strain. 
Some may ask why we choose to look at viral t-Ag DNA and not T-Ag. It is opportune to refer 
that most detection studies by other groups have been designed targeting the JCV large-T antigen, 
which is common to other viruses, such as BK and SV40, to the point that these viruses cannot be 
discriminated by antibodies against T-Ag due to cross-reaction. In addition, a similar problem might 
occur in PCR if it is not nested. This is a reasonable explanation for the wide variation among different 
studies targeting T-Ag, particularly in earlier studies on JCV prevalence. Attending these findings, and 
considering that the restriction of the pathogenic role to a single viral protein (T-Ag) is an 
oversimplification, we chose to use an alternative viral sequence as target. 
 
Although our data cannot support or exclude the following considerations, some authors 
explain this variability in JCV detection, in an infected colon, through the viral integration in the 
genome of some host-cells, with partial loss of JCV DNA. This event may have, in fact, a pathologic 
role in cancer development and can trigger additional processes leading to cancer progression by the 
selection of a cell subpopulation (Figure 1). Furthermore, the inflammatory infiltration itself, caused 
by a local chronic infection in the colon, can also contribute to the selection and expansion of a 
tumour-prone cell[1,34,38,42,43]. 
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Concerning the viral shedding in urine, some studies showed that, in cancer patients, viruria 
can be detected in up to 45% of the cases, even when JCV DNA could not be detected in 
adenoma/adenocarcinoma tissues[44]. Considering just the Portuguese population, only two related 
studies characterize the molecular epidemiology of the urinary excretion of JCV[45,46] both in 
healthy individuals (with excretion rates of 24% and 33%, respectively) and in HIV patients (with 
excretion rates of 51%) and that it is highly variable between genders and influenced by age[46]. Our 
findings point to a higher frequency of the virus in urine of both control and study groups, either 
dependent on the reduced number of specimens, the optimized DNA extraction protocol or the higher 
sensitivity of our set of primers. 
 
To our knowledge, a critical issue in order to determine if JCV contributes to CRC is, indeed, 
its presence in the normal mucosa surrounding the colonic lesions, either adjacent or non-adjacent. If 
we presume that JCV infection plays no role in the colorectal carcinogenesis, then the values for its 
detection should be similar, regardless of the mucosa type (normal/abnormal), which is not the case of 
the results from our study. But if we consider that JCV presence is able to facilitate tumour 
development, DNA sequences should be detected at significant levels in the tumour tissue. 
 
Our analysis of the comparison between colonic lesions and the surrounding normal mucosa 
showed that the frequency is, in fact, higher in the tumour tissue than in the matched pairs of normal 
mucosa. Furthermore, in this context it is important to emphasize that there were no significant 
differences between the values observed for the normal mucosa surrounding the lesions versus the 
control mucosa, which are in consonance with the lack of significance between the two groups of 
patients concerning to the viral urinary secretion. 
These data show us the epidemiological extent of the JCV infection in the normal Portuguese 
population, detectable in both normal colorectal mucosa and urine. But in a subgroup of patients with 
colorectal lesions, the higher prevalence of JCV DNA suggests that a biological selection of the JCV 
infected cells occurs during tumourigenesis. 
 
2.6. Conclusions 
The role of JC virus in carcinogenesis is still an open issue in the pathogenesis of colorectal 
cancer. Even with substantial discrepancies, probably dependent of variables such as geography, 
genetic background and technical approach, JCV has been successfully detected in several studies 
concerning to its association with CRC development. 
The high prevalence rates, found for the presence of JCV DNA in the colorectal mucosa and 
urine, seems to be based on the our experimental approach and the selected set of primers, with newly 
designed oligonucleotide sequences complementary to the viral gene encoding t-Ag. These primers are 
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probably more accurate for the detection of JCV genome, either in colorectal mucosa or in urine 
samples, than those targeted for large T-antigen, when there is partial DNA loss due to vital 
integration, with consequent lack of target for primer amplification. The integration of viral DNA in 
viruses-associated tumours is a well known phenomenon, namely for viruses such as HPV and HBV. 
The results of this study allowed us to consider that the presence of JCV DNA in colorectal 
lesions is an early and sustained event during tumour progression, unrelated with the lesion type, grade 
or severity, and that JCV may have a specific tropism for CRC and colorectal polyps. This observation 
may reflect a condition where the transformed colorectal epithelial cells offer a more permissive 
environment for viral DNA replication, being effective even since the hyperplastic polyps not prone to 
carcinogenesis. In fact, all together, our findings suggest that JC polyomavirus infection may precede 
the colorectal lesion occurrence, acting as an additional risk factor, or just be related with its 
progression, acting as a carcinogenic enhancer. 
 
Furthermore, we propose the epidemiological extent of the JCV infection in the 
gastrointestinal and urinary tracts of the normal Portuguese population, and a biological selection of 
JCV infected cells during tumourigenesis in individuals with colorectal lesions. 
 
On the other hand, the inflammatory infiltration caused by the local chronic infection of the 
colorectal mucosa can contribute, itself, to the selection and expansion of tumour-prone cells. In this 
context, JCV may assume an important role as a co-factor in neoplastic transformation and 
development of colonic tumours. This is an issue that has not been explored in the context of 
gastrointestinal JCV infection and which deserves further attention, particularly if considering that 
chronic inflammation is a risk factor in colorectal cancer. 
 
Finally, we consider that the short-term planning of strategies to reduce the burden of JCV in 
the population might contribute to reduce the incidence of colorectal cancer, similarly to other human 
cancer associated to infectious agents. In addition, the local inflammatory reaction in response to 
chronic infection, even if mild, might also be an important factor to facilitate tumour development, and 
it can also be a target in order to reduce its risk. 
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2.9. Figures and Tables 
FIGURE 2.1 
A: 1st Nested-PCR reaction using the external set of primers; 1 
extracted from colorectal mucosa samples ; 3 
pBR322 – BamHI with JCV-Mad-1 genome); 
B: 2nd Nested-PCR reaction using the internal set of primers; 4 
extracted from colorectal mucosa samples ; 6 
pBR322 – BamHI with the JCV-Mad
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TABLE 2.1. Relationship between JCV DNA presence/absence and colorectal lesions characteristics. 
n=100 
 JCV 
Number of Patients Presence Absence 
1. Hyperplastic polyps 26 23 3 
     1.1. Male/Female ratio 18/8 16/6 2/2 
     1.2. Location    
          1.2.1. Rectum 11 11 0 
          1.2.2. Sigmoid colon 15 12 3 
2. Adenomas 60 55 5 
     2.1. Male/Female ratio 41/19 38/17 3/2 
     2.2 Histological type    
          2.2.1. Villous 7 7 0 
          2.2.2. Tubular 42 39 3 
          2.2.3. Tubulovillous 11 9 2 
     2.3. Grade of dysplasia    
          2.3.1. High-grade 1 1 0 
          2.3.2. Low-grade 59 57 2 
     2.4. Location    
          2.4.1. Right colon 10 10 0 
          2.4.2. Left colon 50 45 5 
3. Adenocarcinomas 14 12 2 
     3.1. Male/Female ratio 8/6 7/5 1/1 
     3.2. Dukes stage    
          3.2.1. A 3 2 1 
          3.2.2. B 2 2 0 
          3.2.3. C 6 5 1 
          3.2.4. D 3 3 0 
     3.3. Degree of differentiation    
          3.3.1. Good 9 8 1 
          3.3.2. Moderate 5 4 1 
          3.3.3. Poor 0 0 0 
     3.4. Location    
          3.4.1. Right colon 2 2 0 
          3.4.2. Left colon 12 10 2 
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FIGURE 2.2 
A: Relative frequency in the samples of the control group (with no colorectal lesions), for the presence (JVC positive) and
absence (JCV negative) of JCV DNA sequences; studied samples correspond to normal colorectal mucosa and urine; the 
percentages refer to relative frequency;
B: Relative frequency in the samples of the study group (with, at least, one colorectal hyperplastic polyp, adenoma or 
adenocarcinoma), for the presence (JCV positive) and
correspond to colorectal lesions, normal adjacent and non
frequency; 
C: Comparison between normal colorectal mucosa samples from the study group and from the control group, for the presence 
(JCV positive) and absence (JCV negative) of JCV
D: Comparison between urine samples from the study group and from the control group, for the 
absence (JCV negative) of JCV DNA sequences.
elopment
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OD=Odds Ratio 
CI=Confidence Intervals 
TABLE 2.2. Risk estimate (Odds Ratio=OD) and Confidence Intervals (CI) for the presence of JCV DNA sequences 
in colorectal lesions (hyperplastic polyps/adenomas/adenocarcinomas) versus the other biological specimens from the 
study group. 
 
Odds Ratio 
(OD) 
Confidence 
intervals 
(CI-95%) 
Significance p Value 
Colorectal Lesions 
vs. 
Normal adjacent mucosa 
9.75 4.550-20.90 **** p<0.0001 
Colorectal Lesions 
vs. 
Normal non-adjacent mucosa 
12.95 6.024-27.84 **** p<0.0001 
Colorectal Lesions 
vs. 
Urine 
10.29 4.497-23.52 **** p<0.0001 
Assessment of JC polyomavirus in normal colorectal
and adenocarcinomas in a Portuguese population and its association with cancer development
 
FIGURE 2.3 
Different combinations (phenotypes) of the sample type for the presence (P) and absen
A: in the control group (studied samples correspond to normal 
B: in the study group (studied samples correspond to 
lesions). 
P=Presence of JCV DNA 
A=Absence of JCV DNA 
 
 mucosa, hyperplastic polyps and sporadic adenomas 
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*Significant 
P=Presense 
A=Absence 
TABLE 2.3. Absolute frequency of the presence (P)/absence (A) of JCV DNA sequences in the observed combinations 
(phenotypes) of the sample types (normal non-adjacent mucosa, normal adjacent mucosa, lesions and urine). 
 Phenotypes 
Control Group 
(Normal Colorectal Mucosa/Urine) 
n=30 
 
(P)/(P) 
 
(P)/(A) 
 
(A)/(P) 
 
(A)/(A) 
20 5 0 5 
p Value (X2)  <0.0001 (22.50)*   
Study Group 
(Normal Non-Adjacent Mucosa/Normal Adjacent Mucosa/Lesions) 
n=100 
(P)/(P)/(P) (A)/(A)/(A) (A)/(P)/(P) (A)/(A)/(P) (P)/(A)/(P) 
     30       10         18 31 11 
p Value (Χ2)   <0.0001 (25.38)*   
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2.10. Appendix A 
2.10.1. Appendix A.I 
CRITÉRIOS DE INCLUSÃO E EXCLUSÃO 
COLONOSCOPIA E BIÓPSIA COLORRECTAL 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
1. Critérios Gerais de Inclusão no Protocolo de Estudo 
 
Deverão ser incluídos no protocolo de estudo os indivíduos que possuam uma das seguintes 
características: 
 
1.1 - Doentes com indicação clínica de realização de colonoscopia e eventual biópsia 
diagnóstica/terapêutica, numa das seguintes situações: 
  - Sangramento digestivo; 
- Diarreia crónica; 
  - Doença inflamatória crónica do cólon; 
  - Estenoses cólicas; 
- Parasitoses; 
- Pólipos do cólon e/ou reto identificados durante o exame; 
  - Tumores colorrectais. 
 
1.2 - Doentes com indicação de colheita de biópsia: 
- Em qualquer uma das situações anteriores, desde que haja indicação de biópsia; 
- Em qualquer outra situação clínica que necessite de biópsia diagnóstica (ex.: 
fasciolíase). 
 
Nota: Os exames deverão ser indicados para avaliação diagnóstica elegível de quadros clínicos 
sugestivos de alterações colorrectais e no seguimento de tratamentos clínicos e cirúrgicos em doentes 
em ambulatório e internados. 
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1.3 - Doentes com patologias que constituam fatores de risco de desenvolvimento de pólipos 
colorrectais: 
- Doentes com acromegalia, já operados ou não; 
- Doentes com bacteriemia por Streptococcus bovis; 
- Doentes com cancro da mama; 
- Doentes colecistectomizados; 
- Doentes com ureterosigmoidostomia. 
 
1.4 - Doentes de risco de endocardite infeciosa ou portadores de prótese valvar cardíaca desde 
que seja feita antibioticoprofilaxia (ex.: associação de ampicilina e gentamicina); 
 
1.5 - Doentes em uso de terapia anticoagulante desde que sujeitos a suspensão temporária da 
medicação: doentes em uso de anti-agregantes plaquetares ou anti-inflamatórios não-esteróides desde 
que o seu uso seja suspenso nos 7 dias anteriores à data da realização do exame. 
 
 
2. Critérios Gerais de Exclusão no Protocolo de Estudo 
 
Não deverão ser incluídos no protocolo de estudo os indivíduos com uma das seguintes 
condições: 
 
2.1 - Menores de 18 anos; 
 
2.2 - Grávidas (beta-HCG positivo); 
 
2.3 - Doentes com sintomatologia e/ou patologia colo-rectal, sem indicação de biópsia; 
 
2.4 - Peritonite; 
 
2.5 - Distúrbios de coagulação; 
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2.6 - Imunocomprometidos (ex.: diabetes melitus, insuficiência renal, HIV, radioterapia, 
corticoterapia, outros imunossupressores). Nestes casos poderão ser indicados alguns exames para 
avaliar o doente antes de realizar o exame. A contagem de linfócitos T CD4+ deve ser superior a 
200/mm³, ou quando abaixo desse número, os leucócitos devem ser superiores a 3.000/mm³;10 as 
plaquetas devem estar acima de 50.000/mm³; a hemoglobina superior a 10 g/dl e o tempo de 
protrombina maior que 60%; 
 
2.7 - Dispneia; 
 
2.8 - Cardiopatia avançada; 
 
2.9 - Doentes sem autonomia; 
 
2.10 - Doentes não colaborantes; 
 
2.11 - Doentes que apresentem mau estado geral; 
 
2.12 - A não concordância com os termos do Consentimento Livre Esclarecido; 
 
2.13 - Síndromas hereditários: Polipose Adenomatosa Familiar e Síndroma de Lynch; 
 
2.14 - Indicação para realização urgente de colonoscopia (ex.: quadro oclusivo, hemorragia 
digestiva com repercussão hemodinâmica). 
 
 
Nota: Entre os riscos acrescidos à realização de biópsia conta-se a bacteriemia pós-
colonoscopia. Na população em geral a incidência está em torno de 0% a 5%, independente de biópsia 
ou polipectomia. 
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2.10.2. Appendix A.II 
FORMULÁRIO DE RECOLHA DE DADOS 
PROJETO POLIOMAVÍRUS 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
 
 
 
 
HOSPITAL:_________________________ 
SERVIÇO:__________________________ 
N.º REGISTO/ENTRADA:________/_____ 
DATA:_____/______/______ 
DOENTE A INCLUIR NO GRUPO:_____________________________ 
DADOS PESSOAIS 
APELIDO  SEXO: M 
NOME  F 
DATA DE NASCIMENTO ___/___/_______  
ORIGEM GEOGRÁFICA: CONCELHO  
 
DISTRITO 
 
MORADA ACTUAL  
 
CÓDIGO POSTAL ______ - ____ LOCALIDADE  
AGREGADO FAMILIAR ____pess. ESCOLARIDADE  
 PROFISSÃO  
 
HÁBITOS TABÁGICOS N   
 
S CONSUMO DIÁRIO: MENOS DE 1 MAÇO  
 
1-2 MAÇOS 
 
MAIS DE 2 MAÇOS 
 
HÁBITOS ALCOÓLICOS N  
 
S 
 
 
Etiqueta do doente 
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DADOS CLÍNICOS 
N.º PROCESSO CLÍNICO  DATA DE ENTRADA 
___/___/______ 
MÉDICO ASSISTENTE  N.º MECANOGRÁFICO  
SERVIÇO  
DIAGNÓSTICO CLÍNICO  
IDADE AQUANDO DO DIAGNÓSTICO _____ anos  
TIPO DE INTERVENÇÃO: BIÓPSIA DIAGNÓSTICA  
 
BIÓPSIA TERAPÊUTICA  
CIRURGIA DE RESSECÇÃO TUMORAL  
COLECTOMIA  
OUTRA  QUAL: 
 
HISTÓRIA CLÍNICA 
ANTERIOR 
 
 
 
 
 
 
HISTÓRIA FAMILIAR 
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DADOS DA COLHEITA 
DATA DA COLHEITA ___/___/______ HORA DA COLHEITA __:__ 
MÉDICO REQUISITANTE  N.º MECANOGRÁFICO  
SERVIÇO  
TIPO DE MATERIAL BIOLÓGICO: SANGUE PERIFÉRICO   
 
URINA 
 
ESFREGAÇO BUCAL 
 
TECIDO FRESCO 
 
TECIDO PARAFINADO 
 
TECIDO CONGELADO 
 
OUTRO 
 
QUAL: 
N.º DE AMOSTRAS COLHIDAS  DESIGNAÇÃO 1 -  
 2 -  
3 -  
4 -  
DESCRIÇÃO DAS AMOSTRAS 1 -  
 
2 -  
3 -  
4 -  
DESIGNAÇÃO CORRESPONDENTE 
DA AMOSTRA ENVIADA À ANATOMIA-
PATOLÓGICA 
1 -  
2 -  
3 -  
4 -  
 
DIAGNÓSTICO ANATOMO-PATOLÓGICO 
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2.10.3. Appendix A.III 
FORMULÁRIO DE CONSENTIMENTO LIVRE ESCLARECIDO 
(De acordo com a versão oficial de 2004 da Declaração de Helsínquia sobre os Princípios Éticos de Investigação Médica 
Em Humanos e com a Convenção para a Proteção dos Direitos do Homem e da Dignidade do Ser Humano face às 
Aplicações da Biologia e da Medicina ratificada pela Resolução da Assembleia da República n.º 1/2001, de 3 de Janeiro) 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
Para doentes com patologia colorrectal a serem submetidos a colonoscopia e eventual 
biópsia diagnóstica/terapêutica 
 
I. INTRODUÇÃO 
 
Está a ser convidado(a) para fazer parte de um estudo de investigação. Antes de decidir fazer 
parte deste estudo, é necessário que compreenda os riscos e os benefícios envolvidos. Este formulário 
de consentimento fornece informações sobre o estudo de investigação. Um membro do grupo de 
investigação, envolvido neste estudo, estará sempre ao seu dispor para responder às suas perguntas e 
fornecer explicações adicionais sempre que as solicitar. Se concordar em fazer parte deste estudo de 
investigação, ser-lhe-á pedido que assine este formulário de consentimento. Este processo é conhecido 
por consentimento livre esclarecido ou com conhecimento de causa. A decisão é sua, sendo livre de 
optar entre fazer ou não parte deste estudo. 
 
II. OBJETIVO 
 
Este projeto de investigação tem como principais objetivos: o estabelecimento de uma 
correlação entre a infeção por poliomavírus neurotrópico humano (JCV) e o desenvolvimento de 
cancro colorrectal numa população Portuguesa; a avaliação dos respetivos fatores modificadores do 
risco e seu valor como fator de prognóstico; e a identificação dos mecanismos da carcinogénese 
colorrectal potencialmente mediada pelo vírus. Uma vez comprovada esta associação, será possível 
identificar os indivíduos de risco para o desenvolvimento de cancro colorrectal, ajustar a vigilância 
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clínica para um diagnóstico precoce e identificar, a longo prazo, possíveis alvos terapêuticos, quer 
virais, quer da célula hospedeira, com o intuito de controlar a patogenicidade do JCV. 
Para avaliar a frequência da infeção pelo vírus JC em indivíduos portadores de cancro 
colorrectal, é necessário estudar mucosa colorrectal com lesão tumoral em vários estadios, mucosa 
colorrectal com lesão precursora de tumor, mucosa colorrectal com lesão não oncológica e mucosa 
normal adjacente às lesões. Pelo que fragmentos das amostras que poderão ser colhidas da sua mucosa 
colorrectal serão destinados a este projeto de investigação, desde que o consinta por escrito. 
 
III. PROCEDIMENTOS 
 
Ao concordar em participar, permite que, durante a realização da sua colonoscopia de 
diagnóstico ou de tratamento, se forem colhidas biópsias de mucosa do cólon, alguns fragmentos 
destas podem ser utilizados, no âmbito deste projeto, para estudos moleculares. A realização deste 
estudo não altera em nada o seu protocolo de tratamento e vigilância. 
 
IV. POSSÍVEIS RISCOS 
 
Os riscos associados às colheitas de mucosa colorrectal, por biópsia colonoscópica, são os 
mesmos associados às colheitas do material para diagnóstico ou tratamento da sua patologia, porque 
derivam dessas colheitas, sem que haja qualquer colheita adicional. 
 
V. POSSÍVEIS BENEFÍCIOS 
 
Com a sua participação neste estudo não existirá um benefício imediato para si, quer financeiro 
quer de qualquer outra natureza. No entanto, espera-se que o resultado deste projecto de investigação 
conduza à identificação de indivíduos de risco para o desenvolvimento de cancro colorrectal. Se for o 
seu caso, poderá beneficiar de uma adequada estratégia de vigilância e diagnóstico precoce. Mais se 
espera, com o seu contributo pessoal, melhorar o entendimento da carcinogénese colorrectal, mediada 
pelo vírus JC, e o respectivo tratamento. 
 
VI. CONSENTIMENTO PARA UTILIZAÇÃO E ELIMINAÇÃO DAS AMOSTRAS 
 
Através da assinatura deste formulário de consentimento, autoriza a utilização das suas 
amostras de mucosa colorrectal, colhidas por biópsia colonoscópica, para este estudo de investigação. 
Simultaneamente consente na eliminação, após manipulação, de qualquer tecido restante ou que não 
seja adequado ao estudo. 
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VII. CUSTOS 
 
Não incorrerá em quaisquer despesas com a colheita das amostras, análises, testes e avaliações 
exigidas por este protocolo. 
 
VIII. COMPENSAÇÕES 
 
Não está disponível qualquer tipo de compensação financeira (nenhum tipo de pagamento) ou 
afim, para os participantes neste estudo. 
 
IX. DIREITO A DESISTIR DO ESTUDO 
 
A sua participação neste estudo de investigação é voluntária. Poderá decidir não começar ou 
cessar a sua participação neste estudo em qualquer altura que pretenda. Os cuidados que receber e as 
relações que estabelecer, com os prestadores de assistência médica dos Hospitais da Universidade de 
Coimbra, não serão afectados de maneira nenhuma. Ser-lhe-ão comunicadas quaisquer novas 
informações, sobre o estudo de investigação, que possam fazer com que mude de opinião sobre a sua 
participação. Deverá notificar um dos elementos do grupo de investigação, caso decida cessar a sua 
participação antes do tempo previsto. 
 
X. CONFIDENCIALIDADE DOS RELATÓRIOS MÉDICOS E DA INVESTIGAÇÃO 
 
Todos os seus dados pessoais e registos médicos, excepto no que se refere à equipa clínica e 
aos médicos integrantes do grupo de investigação, e todos os resultados do estudo de investigação, 
excepto no que se refere à equipa clínica e ao grupo de investigação, serão mantidos em sigilo, a 
menos que sejam exigidos por decisão judicial. 
 
XI. PERGUNTAS 
 
Se necessitar de algum esclarecimento relacionado com este trabalho de investigação ou se 
sentir algum efeito secundário ou lesão que possa estar relacionada com a sua participação no estudo, 
poderá contactar um dos elementos do grupo de investigação. 
Os investigadores Mestre Tatiana Andrea Rasteiro Coelho e Prof. Doutor Luís Almeida serão 
responsáveis pelo esclarecimento, antes e após a colheita, de qualquer dúvida, pessoalmente, por 
telefone (239480054/916584854/912133241) ou por e-mail (tatiana.coelho@sapo.pt/ 
lalmeida@ci.uc.pt). 
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XII. ASSINATURAS 
 
Através da assinatura deste formulário de consentimento livre esclarecido, afirma que leu o seu 
conteúdo, que os objetivos e procedimentos deste estudo lhe foram explicados e que todas as suas 
perguntas foram devida- e claramente respondidas. Não estará a abdicar de nenhum dos seus direitos 
legais, ao assinar este formulário. Adicionalmente afirma também que todas as informações prestadas 
por si, acerca dos antecedentes clínicos, são verdadeiras. Caso solicite, ser-lhe-á fornecida uma cópia 
deste consentimento. 
 
Eu, __________________________    _______ ____, 
portador(a) do B.I. n.º    , emitido em   / /  pelo Arquivo 
de Identificação de     ,e abaixo assinado(a), li e compreendi tudo o que 
consta neste formulário e esclareci todas as minhas dúvidas acerca da minha participação neste 
projecto de investigação, pelo que: 
 
1 - Concordo em participar neste estudo, através da utilização da(s) minha(s) amostra(s) de 
mucosa colorrectal, colhida(s) aquando da realização de colonoscopia e biópsia para diagnóstico da 
minha patologia: 
sim ( ) 
não ( ) 
 
2 – Visto que respondi sim, também concordo com o estudo e posterior divulgação científica 
dos dados obtidos a partir da(s) minha(s) amostra(s): 
sim ( ) 
não ( ) 
 
3 - Concordo com a posterior divulgação científica das imagens obtidas a partir da(s) minha(s) 
amostra(s): 
sim ( ) 
não ( ) 
 
4 – Pretendo tomar conhecimento dos resultados referidos nas duas alíneas anteriores: 
sim ( ) 
não ( ) 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
49 
 
Coimbra, ______ de _________________ de 20___ 
O participante 
            
 
Coimbra, ______ de _________________ de 20___ 
 
O seu representante autorizado 
            
Relação com o participante:      
 
Se o participante puder compreender o conteúdo mas não puder, por alguma razão, ler (ex.: 
cegueira, etc.) ou não puder assinar (ex.: incapacidade motora, etc.) o formulário de consentimento 
livre esclarecido, será necessária a presença de uma testemunha não relacionada com o estudo. 
 
Coimbra, ______ de _________________ de 20___ 
 
A testemunha 
            
 
Coimbra, ______ de _________________ de 20___ 
 
Nome e Assinatura dos Investigadores 
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FORMULÁRIO DE CONSENTIMENTO LIVRE ESCLARECIDO 
(De acordo com a versão oficial de 2004 da Declaração de Helsínquia sobre os Princípios Éticos de Investigação Médica Em 
Humanos e com a Convenção para a Proteção dos Direitos do Homem e da Dignidade do Ser Humano face às Aplicações da 
Biologia e da Medicina ratificada pela Resolução da Assembleia da República n.º 1/2001, de 3 de Janeiro) 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
Para doentes a submeter a cirurgia colorrectal de ressecção tumoral 
 
I. INTRODUÇÃO 
 
Está a ser convidado(a) para fazer parte de um estudo de investigação. Antes de decidir fazer 
parte deste estudo, é necessário que compreenda os riscos e os benefícios envolvidos. Este formulário 
de consentimento fornece informações sobre o projeto de investigação. Um membro do grupo de 
investigação, envolvido neste estudo, estará sempre ao seu dispor para responder às suas perguntas e 
fornecer explicações adicionais sempre que as solicitar. Se concordar em fazer parte deste estudo de 
investigação, ser-lhe-á pedido que assine este formulário de consentimento. Este processo é conhecido 
por consentimento livre esclarecido ou com conhecimento de causa. A decisão é sua, sendo livre de 
optar entre fazer ou não parte deste estudo. 
 
II. OBJECTIVOS 
 
Este projeto de investigação tem como principais objetivos: o estabelecimento de uma 
correlação entre a infecção por poliomavírus neurotrópico humano (JCV) e o desenvolvimento de 
cancro colo-rectal numa população Portuguesa; a avaliação dos respectivos fatores modificadores do 
risco e seu valor como fator de prognóstico; e a identificação dos mecanismos da carcinogénese colo-
rectal potencialmente mediada pelo vírus. Uma vez comprovada esta associação, será possível 
identificar os indivíduos de risco para o desenvolvimento de cancro colo-rectal, ajustar a vigilância 
clínica para um diagnóstico precoce e identificar, a longo prazo, possíveis alvos terapêuticos, quer 
virais, quer da célula hospedeira, com o intuito de controlar a patogenicidade do JCV. 
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Para avaliar a frequência da infecção pelo vírus JC em indivíduos portadores de cancro colo-
rectal, é necessário estudar mucosa colo-rectal com lesão tumoral em vários estadios, mucosa colo-
rectal com lesão precursora de tumor, mucosa colo-rectal com lesão não oncológica e mucosa normal 
adjacente às lesões. É para esta finalidade, se assim o consentir, que se destina o material biológico 
que for colhido durante a sua cirurgia. 
 
III. PROCEDIMENTOS 
 
Ao concordar em participar, permite que, durante o processamento da sua peça cirúrgica para 
tratamento e posterior diagnóstico, sejam colhidas amostras de mucosa do cólon para estudos 
moleculares. A realização deste estudo não altera em nada o seu protocolo de tratamento e vigilância, 
visto que não haverá colheita de amostras adicionais. 
 
IV. POSSÍVEIS RISCOS 
 
Esta colheita não incorre em quaisquer riscos adicionais, para além dos associados ao ato 
cirúrgico previsto. 
 
V. POSSÍVEIS BENEFÍCIOS 
 
Com a sua participação neste estudo não existirá um benefício imediato para si, quer financeiro 
quer de qualquer outra natureza. No entanto, espera-se que o resultado deste projeto de investigação 
conduza à identificação de indivíduos de risco para o desenvolvimento de cancro colo-rectal. Se for o 
seu caso, poderá beneficiar de uma adequada estratégia de vigilância e diagnóstico precoce. Mais se 
espera, com o seu contributo pessoal, melhorar o entendimento da carcinogénese colo-rectal, mediada 
pelo vírus JC, e o respectivo tratamento. 
 
VI. CONSENTIMENTO PARA UTILIZAÇÃO E ELIMINAÇÃO DAS AMOSTRAS 
 
Através da assinatura deste formulário de consentimento, autoriza a utilização das suas 
amostras de mucosa colo-rectal, colhidas da peça operatória após processamento para diagnóstico, 
neste estudo de investigação. Simultaneamente, consente na eliminação, após manipulação, de 
qualquer tecido restante ou que não seja adequado ao estudo. 
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VII. CUSTOS 
 
Não incorrerá em quaisquer despesas com a colheita das amostras, análises, testes e avaliações 
exigidas por este protocolo. 
 
VIII. COMPENSAÇÕES 
 
Não está disponível qualquer tipo de compensação financeira (nenhum tipo de pagamento) ou 
afim, para os participantes neste estudo. 
 
IX. DIREITO A DESISTIR DO ESTUDO 
 
A sua participação neste estudo de investigação é voluntária. Poderá decidir não começar ou 
cessar a sua participação neste estudo em qualquer altura que pretenda. Os cuidados que receber e as 
relações que estabelecer, com os prestadores de assistência médica, não serão afectados de maneira 
nenhuma. Ser-lhe-ão comunicadas quaisquer novas informações, sobre o estudo de investigação, que 
possam fazer com que mude de opinião sobre a sua participação. Deverá notificar um dos elementos 
do grupo de investigação, caso decida cessar a sua participação antes do tempo previsto. 
 
X. CONFIDENCIALIDADE DOS RELATÓRIOS MÉDICOS E DA INVESTIGAÇÃO 
 
Todos os seus dados pessoais e registos médicos, excepto no que se refere à equipa clínica e 
aos médicos integrantes do grupo de investigação, e todos os resultados do estudo de investigação, 
exceto no que se refere à equipa clínica e ao grupo de investigação, serão mantidos em sigilo, a menos 
que sejam exigidos por decisão judicial. 
 
XI. PERGUNTAS 
 
Se necessitar de algum esclarecimento relacionado com este trabalho de investigação ou se 
sentir algum efeito secundário ou lesão que possa estar relacionada com a sua participação no estudo, 
poderá contactar um dos elementos do grupo de investigação. 
Os investigadores Mestre Tatiana Andrea Rasteiro Coelho e Prof. Doutor Luís Almeida serão 
responsáveis pelo esclarecimento, antes e após a colheita, de qualquer dúvida, pessoalmente, por 
telefone (239480054/916584854/912133241) ou por e-mail (tatiana.coelho@sapo.pt 
/lalmeida@ci.uc.pt). 
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XII. ASSINATURAS 
 
Através da assinatura deste formulário de consentimento livre esclarecido, afirma que leu o seu 
conteúdo, que os objetivos e procedimentos deste estudo lhe foram explicados e que todas as suas 
perguntas foram devida- e claramente respondidas. Não estará a abdicar de nenhum dos seus direitos 
legais, ao assinar este formulário. Adicionalmente, afirma também que todas as informações prestadas 
por si, acerca dos antecedentes clínicos, são verdadeiras. Caso solicite, ser-lhe-á fornecida uma cópia 
deste consentimento. 
 
Eu, __________________________    _______ ____, 
portador(a) do B.I. n.º    , emitido em   / /  pelo Arquivo 
de Identificação de     ,e abaixo assinado(a), li e compreendi tudo o que 
consta neste formulário e esclareci todas as minhas dúvidas acerca da minha participação neste projeto 
de investigação, pelo que: 
 
1 - Concordo em participar neste estudo, através da colheita de amostra(s) de mucosa colo-
rectal da minha peça operatória, após manipulação e processamento para diagnóstico/tratamento da 
minha patologia: 
sim ( ) 
não ( ) 
 
2 – Visto que respondi sim, também concordo com o estudo e posterior divulgação científica 
dos dados obtidos a partir da(s) minha(s) amostra(s): 
sim ( ) 
não ( ) 
 
3 - Concordo com a posterior divulgação científica das imagens obtidas a partir da(s) minha(s) 
amostra(s): 
sim ( ) 
não ( ) 
 
4 – Pretendo tomar conhecimento dos resultados referidos nas duas alíneas anteriores: 
sim ( ) 
não ( ) 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
55 
 
Coimbra, ______ de _________________ de 20___ 
 
O participante 
            
 
Coimbra, ______ de _________________ de 20___ 
 
O seu representante autorizado 
            
Relação com o participante:      
 
Se o participante puder compreender o conteúdo mas não puder, por alguma razão, ler (ex.: 
cegueira, etc.) ou não puder assinar (ex.: incapacidade motora, etc.) o formulário de consentimento 
livre esclarecido, será necessária a presença de uma testemunha não relacionada com o estudo. 
 
Coimbra, ______ de _________________ de 20___ 
 
A testemunha 
            
 
Coimbra, ______ de _________________ de 20___ 
 
Nome e Assinatura dos Investigadores 
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TERMO DE CONSENTIMENTO LIVRE ESCLARECIDO 
(De acordo com a versão oficial de 2004 da Declaração de Helsínquia sobre os Princípios Éticos de Investigação Médica 
Em Humanos e com a Convenção para a Proteção dos Direitos do Homem e da Dignidade do Ser Humano face às 
Aplicações da Biologia e da Medicina ratificada pela Resolução da Assembleia da República n.º 1/2001, de 3 de Janeiro) 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
DECLARAÇÃO 
 
Eu, __________________________    _______ ____, 
portador(a) do B.I. n.º    , emitido em   / /  pelo Arquivo 
de Identificação de     ,e abaixo assinado(a), declaro que fui devidamente 
informado(a) e esclarecido(a) acerca do constante no consentimento livre esclarecido e que se resume 
a seguir: 
 
1. - Um grupo de investigação da Faculdade de Medicina da Universidade de Coimbra 
encontra-se a desenvolverumo projeto de investigação intitulado "Assessment of JC polyomavirus in 
normal colorectal mucosa, hyperplastic polyps and sporadic adenomas and adenocarcinomas in a 
portuguese population and its association with cancer development", no qual se pretende detetar e 
identificar o poliomavírus neurotrópico humano JC, em amostras humanas da mucosa do cólon, 
visando o estudo da prevalência da infeção viral, numa população portuguesa, e a avaliação do risco 
de desenvolvimento de doenças oncológicas colorrectais. 
 
2. - A equipa de investigadores, representada pelo Prof. Doutor Luís Manuel da Costa 
Marques de Almeida e pela Mestre Tatiana Andrea Rasteiro Coelho, é responsável pelo 
esclarecimento, antes e após a colheita, de qualquer dúvida, por telefone (912133241 ou 916584854) 
ou por e-mail (lalmeida@ci.uc.pt/tatiana.coelho@sapo.pt) e pelo levantamento e análise das 
amostras. 
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3. – Os procedimentos a que serei submetido(a) para a obtenção destas amostras, os 
respectivos benefícios, riscos, complicações potenciais e alternativas decorrentes da minha 
participação foram-me descritos pelo médico especialista responsável pela colheita, o qual me 
garantiu que em nada colidem com todos os actos médicos que seriam praticados sem a existência 
desta investigação. 
 
Mais declaro que: 
 
1. – Me foi garantida a anulação do consentimento livre esclarecido, a qualquer momento, 
sem que disto decorra qualquer penalidade ou interrupção dos actos médicos referidos na alínea 
anterior. 
 
2. – Me foi garantida a manutenção da total confidencialidade dos meus dados pessoais, em 
qualquer circunstância. 
 
3. – Até ao momento, tive a oportunidade de colocar quaisquer questões, as quais foram 
pronta- e satisfatoriamente respondidas. 
 
4. - Recebi explicações, li, compreendi e concordo com os itens acima referidos e que me foi 
dado a oportunidade de expressar sobre os pontos com os quais não concordasse. 
 
Após a leitura e a integral compreensão dos itens do consentimento livre esclarecido que me 
foi facultado, eu           declaro que: 
 
1 - Concordo em participar nesta investigação, através da colheita de amostras adicionais da 
minha mucosa colorrectal aquando da realização da biópsia de diagnóstico e/ou terapêutica: 
sim ( ) 
não (.) 
 
2 – Visto que respondi sim, também concordo com o estudo e posterior divulgação científica 
dos dados obtidos a partir da(s) minha(s) amostra(s): 
sim ( ) 
não ( ) 
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3 - Concordo com a posterior divulgação científica das imagens obtidas a partir da(s) 
minha(s) amostra(s): 
sim ( ) 
não ( ) 
 
4 – Pretendo tomar conhecimento dos resultados referidos nas duas alíneas anteriores: 
sim ( ) 
não ( ) 
 
Coimbra, ______ de _________________ de 20___ 
 
O participante 
 
            
 
Nome e Assinatura dos Investigadores 
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2.10.4. Appendix A.IV 
PROTOCOLO DE COLHEITA DE AMOSTRAS 
COLONOSCOPIA E BIÓPSIA COLORRECTAL 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
Para doentes com patologia colorrectal a serem submetidos a colonoscopia e eventual 
biópsia diagnóstica/terapêutica 
 
SERVIÇO DE GASTRENTEROLOGIA – HUC 
(Diretor: Prof. Doutor Maximino Correia Leitão) 
 
I – Colheita de amostras em doentes com patologia colorrectal com indicação para 
colonoscopia e biópsia diagnóstica/terapêutica e que obedeçam aos critérios de inclusão: 
 
I.1 – Assinatura prévia do consentimento livre esclarecido, pelo doente participante: o 
gastrenterologista deverá esclarecer o doente participante sobre o conteúdo do consentimento livre 
esclarecido; o doente participante deverá ler, preencher e assinar o formulário de consentimento livre 
esclarecido para validar a sua inclusão no estudo. 
 
I.2 – Colheita de amostra de urina: previamente à realização do exame colonoscópico, o doente 
deverá receber indicação para a colheita de uma amostra de urina, mediante fornecimento de recipiente 
apropriado (frasco esterilizado de 60ml); finda a colheita, as amostras serão de imediato entregues ao 
investigador responsável da FMUC para acondicionamento apropriado. 
 
I.3 – Biópsia sob colonoscopia: durante o exame colonoscópico diagnóstico/terapêutico 
previsto o gastrenterologista deverá colher: 
- 2 biópsias de mucosa normal, quando a patologia for não-tumoral (grupo controlo); 
- 2 amostras de lesão, 2 amostras de mucosa colorrectal adjacente à lesão e 2 amostras de 
mucosa normal à distância, quando a patologia for tumoral ou pré-tumoral (grupo de estudo). 
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I.4 – Acondicionamento e transporte das amostras biopsadas: finda a colheita, o 
gastroenterologista deverá acondicionar as amostras de biópsia, sem qualquer tratamento (ex.: imersão 
em formol), num recipiente de colheita apropriado; de seguida deverá disponibilizá-las ao investigador 
da FMUC, que será responsável pela sua entrega no Serviço de Anatomia Patológica dos HUC, até 30’ 
após a excisão; na requisição interna, que acompanha as peças ao Serviço de Anatomia Patológica, 
deverá constar a identificação com as palavras-chave “Projeto Poliomavírus”; o gastrenterologista 
poderá contactar os investigadores responsáveis, do Serviço de Anatomia Patológica, para avisar sobre 
o envio das amostras ou para esclarecer qualquer dúvida que surja durante o procedimento. 
 
Investigador Responsável do Serviço de Gastroenterologia - HUC: 
Prof. Doutor Pedro Narra de Figueiredo 
Telf.: 239400483 
E-mail: pnf11@sapo.pt 
 
 
SERVIÇO DE ANATOMIA PATOLÓGICA – HUC 
(Diretora: Dra. Maria Fernanda Xavier da Cunha) 
 
II – Colheita de fragmentos durante exame macroscópico das amostras de biópsia 
colorrectal: 
 
II.1 – O investigador responsável da FMUC deverá entregar as biópsias, no Serviço de 
Anatomia Patológica, juntamente com as requisições internas indicando “Projecto Poliomavírus”, as 
fichas de recolha de dados do doente e os consentimentos livres esclarecidos devidamente assinados. 
 
II.2 - O investigador responsável da FMUC deverá disponibilizar recipientes adequados (tubos 
eppendorf de 1,5ml) contendo 200µl de solução RNAlater (tampão de estabilização específico para 
RNA). 
 
II.3 – Nas amostras de biópsia, o anatomopatologista executará a colheita, desde que a mesma 
não incorra em qualquer prejuízo para o diagnóstico, de 2 fragmentos de mucosa colorrectal 
correspondentes a lesão, a mucosa adjacente de aspeto colonoscópico normal e a mucosa não-
adjacente de aspeto colonoscópico normal. 
 
II.4 – O anatomopatologista deverá colocar cada fragmento, individualmente, num tubo 
contendo a solução RNAlater. 
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II.5 - O anatomopatologista atribui um código a cada fragmento, de acordo com a peça de 
origem, inscrevendo-o em ambos os recipientes, o do fragmento e o da amostra. 
 
II.6 – O investigador responsável da FMUC garante o correto armazenamento e conservação 
dos fragmentos a -80ºC, em caixa adequada e devidamente identificada com o título “Projecto 
Poliomavírus”. 
 
Investigadores Responsáveis do Serviço de Anatomia Patológica - HUC: 
Dr. Mário Rui Silva 
Telf.: 239400524 
E-mail: mtdsil@gmail.com 
 
Dra. Maria Augusta Cipriano 
Telf.: 239400524 
E-mail.: macipriano@huc.min-saude.pt 
 
 
Equipa de Investigação da FMUC: 
Departamento de Farmacologia e Terapêutica Experimental – Unidade de Terapêutica 
Faculdade de Medicina da Universidade de Coimbra 
Pólo III, Sub-unidade 1, Piso 3, Gabinete 3.10 
Azinhaga de Santa Comba – Celas 
3000-354 Coimbra 
Telefone Geral: 239480054 
Fax: 239480065 
Tlm: Prof. Doutor Luís Almeida - 912133241 
Tlm: Mestre Tatiana Coelho - 916584854 
E-mail: lalmeida@ci.uc.pt ou tatiana.coelho@sapo.pt 
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PROTOCOLO DE COLHEITA DE AMOSTRAS 
PEÇA DE RESSECÇÃO CIRÚRGICA 
 
Projeto de Investigação: “Assessment of JC polyomavirus in normal colorectal mucosa, 
hyperplastic polyps and sporadic adenomas and adenocarcinomas in a Portuguese population and its 
association with cancer development” 
 
Investigador Principal: Prof. Doutor Luís Manuel da Costa Marques de Almeida, MD, PhD 
Doutoranda: Tatiana Andrea Rasteiro Coelho, MSc e Bolseira da Fundação para a Ciência e a 
Tecnologia 
 
Para doentes a submeter a cirurgia colorrectal de ressecção tumoral 
 
SERVIÇO DE CIRURGIA- CHC 
(Diretor: Prof. Doutor Carlos Manuel da Costa-Almeida) 
 
I – Colheita de amostras em doentes submetidos a cirurgia colorrectal de ressecção 
tumoral e que obedeçam aos critérios de inclusão: 
 
I.1 – Assinatura prévia do consentimento livre esclarecido pelo doente participante: o cirurgião 
deverá esclarecer o doente participante sobre o conteúdo do consentimento livre esclarecido; o doente 
participante deverá ler, preencher e assinar o formulário de consentimento livre esclarecido para 
validar a sua inclusão no estudo. 
 
I.2 – Colheita de amostra de urina: previamente à realização da cirurgia o doente deverá 
receber indicação para a colheita de uma amostra de urina, mediante fornecimento de recipiente 
apropriado (frasco esterilizado de 60ml); finda a colheita, as amostras serão de imediato entregues ao 
investigador responsável da FMUC para acondicionamento apropriado. 
 
I.3 – Colheita de fragmentos a partir da peça operatória: após ressecção da peça operatória o 
cirurgião selecionará macroscopicamente e fará a colheita de 2 amostras do tumor colorrectal, 2 
amostras da mucosa adjacente ao tumor e 2 amostras de mucosa não-adjacente ao tumor, todas elas 
com aproximadamente 1cm. 
 
I.4 – Acondicionamento das amostras: o cirurgião deverá colocar cada amostra num recipiente 
apropriado (tubo eppendorf de 1.5ml) contendo 200µl de solução RNAlater (tampão de estabilização 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
66 
 
específico para RNA), fornecido pelos Investigadores responsáveis da FMUC; os tubos deverão ser 
devidamente identificados com o número de registo/entrada, coincidente com o constante na ficha de 
recolha de dados do doente participante. 
 
I.5 – Recolha das amostras: finda a colheita, o cirurgião deverá contactar os investigadores 
responsáveis da FMUC, para solicitar a recolha das amostras, devendo entrega-las juntamente com as 
fichas de recolha de dados e os termos de consentimento livre esclarecido dos doentes; qualquer 
dúvida que surja durante o procedimento poderá ser esclarecida junto dos investigadores responsáveis 
da FMUC. 
 
Investigador Responsável do Serviço de Cirurgia do CHC: 
Dr. Carlos Eduardo da Costa-Almeida 
Telf.: 239800100 - Ext. 33529 
E-mail: cecalmeida@yahoo.com 
 
 
Equipa de Investigação da FMUC: 
Departamento de Farmacologia e Terapêutica Experimental – Unidade de Terapêutica 
Faculdade de Medicina da Universidade de Coimbra 
Pólo III, Sub-unidade 1, Piso 3, Gabinete 3.10 
Azinhaga de Santa Comba – Celas 
3000-354 Coimbra 
Telefone Geral: 239480054 
Fax: 239480065 
Tlm: Prof. Doutor Luís Almeida - 912133241 
Tlm: Mestre Tatiana Coelho - 916584854 
E-mail: lalmeida@ci.uc.pt ou tatiana.coelho@sapo.pt 
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CHAPTER 3 
 
3. Assessement of TP53 mutational status in normal and dysplastic/neoplastic colorectal mucosa 
3.1. Introduction 
Human colorectal cancer (CRC) has been associated, to some extent, to human neurotropic 
polyomavirus JC (JCV) infection and transforming potential. The large T-antigen (T-Ag) is its main 
viral oncoprotein and, like many other oncoproteins, has been recognized as the most crucial for JCV-
mediated transformation process, within non-permissive cells, being uniquely able to induce malignant 
outgrowth and hyperplasia in cultured cells and in several animal models[1,2,3,4,5]. 
Since JCV is unable to encode its own replication proteins it depends on host-cell machinery to 
replicate its DNA. Once in host-cells JCV translates its early proteins, namely the T-Ag, a 
multifunctional protein with helicase and ATPase activity, which are needed for viral DNA 
replication, and with ability to bind and break DNA[6,7]. Some reports state that T-Ag is not 
significantly exported from the nucleus into the cytoplasm of the infected human host-cells[8] and 
that, in fact, it tends to self perpetuate within infected cells and to immortalize the transformed ones, 
cooperatively with a broad range of cellular proteins, such as p53, pRb, IRS-1 and beta-catenin 
(Diagram3.1)[9,10,11]. 
JCV T-Ag can deregulate control of the cell cycle by interacting with the tumour suppressor 
proteins p53 and pRb, making it unique in the ability to simultaneously disrupt chromosomal integrity 
and inactivate cell cycle checkpoints. These events can lead either to suppression of p21WAF-1/Cip1, 
the downstream regulator of p53, or the liberation of the E2F family of transcription factors from pRb. 
Then, p21WAF-1/Cip1 and E2F stimulate several proteins, essential for cell cycle progression and 
rapid cell proliferation (Diagram 3.1). Furthermore, these coordinated actions permit the replication 
and proliferation of cells with damaged DNA[10,12]. 
T-Ag may also distort control of cellular proliferation by deregulating the Wnt signalling 
pathway through stabilization of beta-catenin[13], interacting with IGF-IR signalling[14] and inducing 
chromosomal instability[15]. In fact, it is believed that JCV can mediate colorectal neoplastic 
process via the deregulation of the Wnt signalling pathway[16]. It has also been proposed that, once 
colon neoplastic epithelial cells have experienced biallelic inactivation of a critical number of tissue-
specific tumour suppressor genes, including APC (Adenomatous Polyposis Coli) and p53, the on-
going effect of the transforming virus may be relatively deleterious[17]. 
p53 was the first cellular protein identified as interacting with JCV T-Ag and, subsequently, a 
critical role in deregulation of the cell growth and in genomic instability of infected host-cells was 
established. 
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Diagram 3.1 - The p53, pRb tumour suppressor pathways. The association of JCV large T-antigen with p53 leads to 
inactivation of p53 and downregulation of p21WAF-1 that eventually affects the status of pRb phosphorylation by cyclin cdk 
and the release of E2F. Further, E2F is liberated from the pRb-E2F complex through the interaction of T-antigen with pRb. 
 
The human p53 protein is coded by a gene located in chromosome 17 (17p13) and that 
includes 11 exons, with a very large intron between exons 1 and 2 (Diagram 3.2). Exon 1 is non-
coding in the human p53 and it has been demonstrated that this region could form a stable stem-loop 
structure which binds tightly to wild type p53 but not to mutant p53[18]. 
 
Diagram 3.2 – Schematized p53 exons: the pink marks denote the UTR’s (untranslated regions), the blue marks denote the 
coding regions and the grey marks denote the internal exons within the introns. 
 
The human wild-type p53 protein contains 393 amino acids and is composed of several 
structural and functional domains: the amino-terminus part (codons 1-44) contains the transactivation 
domain, which is responsible for activating downstream target genes; a proline-rich domain (codons 
58-101) mediates p53 response to DNA damage through apoptosis; the DNA-binding domain (codons 
102-292) is a core domain which consists of a variety of structural motifs (this domain is the target of 
90% of p53 mutations found in human cancers, as a single mutation within this domain can cause a 
major conformational change); and the oligomerization domain (codons 325-356) consists of a β-
strand, which interacts with another p53 monomer to form a dimer, followed by an α-helix which 
mediates the dimerization of two p53 dimers to form a tetramer)[19]. 
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Three putative nuclear localization signals (NLS) have been identified in the C-terminus, 
through sequence similarity and mutagenesis. The most N-terminal NLS (NLSI), which consists of 
three consecutive lysine residues to a basic core, is the most active and conserved domain. 
Furthermore, two putative nuclear export signals (NES) have been identified. The leucine-rich C-
terminal NES, found within the oligomerization domain, is highly conserved and it has been suggested 
that oligomerization can result in masking of the NES, resulting in p53 nuclear retention (Diagram 
3.3)[18,19]. 
 
 
Diagram 3.3 – Schematic representation of the p53 structure. p53 contains 393 amino acids, consisting of three functional 
domains: an N-terminal activation domain, DNA binding domain and C-terminal tetramerization domain. The N-terminal 
domain includes transactivation sub-domain and a PXXP region that is a proline-rich fragment. The central DNA binding 
domain is required for sequence-specific DNA binding and amino acid residues within this domain are frequently mutated in 
human cancer cells and tumour tissues. The Arg175, Gly245, Arg248, Arg249, Arg273, and Arg282 are reported to be 
mutation hot spots in various human cancers. The C-terminal region is considered to perform a regulatory function. Residues 
on this basic C-terminal domain undergo posttranslational modifications including phosphorylation and acetylation. 
 
Previous studies showed that human wild-type p53 is able to repress JCV DNA replication in 
vivo by interacting with JC virus T-Ag which is necessary for initiation and elongation of viral DNA 
replication. Using deletion mutants and tumour-derived point mutations of human p53, the basis of the 
suppression of JCV DNA replication by p53 is suppressed. Deletion of either the amino- or the 
carboxyl-terminal domain of p53 does not interfere with the repression of JCV DNA replication. 
However, deletion of the highly conserved central region of p53 abolished the inhibitory effect on 
replication. The tumour-derived human mutant p53(His273) inhibited JCV DNA replication 
significantly, whereas the tumourigenic mutant p53(His175) has no inhibitory effect. Concomitantly, a 
direct protein–protein interaction between p53 and JCV large T-antigen is lost when using mutants 
which did not affect JCV DNA replication. These results strongly suggest that p53 is able to inhibit 
JCV DNA replication by interacting with JCV T-Ag[20]. 
However, the inhibition of p53 function by T-Ag is necessary for both efficient viral 
replication and cellular transformation of host-cell infected by JC polyomavirus. The analysis of the 
crystal structure of T-Ag in complex with p53 reveals an unexpected hexameric complex of T-Ag 
binding six p53 monomers. The structure also shows that T-Ag binding induces dramatic 
conformational changes at the DNA-binding area of p53, which is achieved partially through an 
unusual “methionine switch” within p53. In the complex structure, T-Ag occupies the whole p53 
DNA-binding surface and likely interferes with formation of a functional p53 tetramer[21]. 
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3.2. Purpose 
It seems that the different outcomes of the JC viral infection probably depend on multiple 
factors, both pathogen-related and host-related. Genomic and proteomic biomarkers are proving to be 
particularly useful in the understanding of disease progression, staging and response to therapy in 
chronic diseases and cancer. 
Since disease/infection progress depends on the host response to viral infection, the 
assessement of the genetic status of JCV infected cells in asymptomatic individuals is a promising 
starting point to look for potential biomarkers for viral infection. 
The main purpose of this experimental work was to evaluate the host-cell genetic conditions 
that may contribute for the progression from a latent to an abortive/transforming JCV infection and act 
as risk modifiers in colorectal carcinogenesis, mediated by JC virus in the infected individuals. Thus, 
we screened for genetic alterations (mutations/polymorphisms) in TP53 that can be potentially able to 
modify p53 protein affinity for and interaction with the viral oncoprotein T-Ag. 
To our knowledge the assessement of host-cell genetic features that can act as potential risk 
modifiers for CRC development in JCV infected individuals, the identifications and establishment of 
new risk factors for JCV-mediated colorectal carcinogenesis in humans may contribute to the a short-
term improvement of both early and differential diagnostic, prognostic and clinical surveillance. 
Once JC virus can participate in different ways in the pathogenesis of colorectal cancer, both 
direct and indirect we additionally assessed the mutational profile of the TP53 gene in the normal 
colorectal mucosa, adenomas and adenocarcinomas from infected and non-infected individuals, both 
from the control and the study group, in order to evaluate the extension of the contribution of the JCV 
infection to the mutagenesis during colorectal cancer development. 
 
3.3. Samples and Methods 
3.3.1. DNA samples 
The mutational screening of the TP53 gene was performed by PCR amplification, followed by 
DNA Sequencing, using total genomic DNA obtained, as previously described in Chapter 2, from: a) 
the normal colorectal mucosa of 100 controls (40 of them positive for JCV DNA) and 100 patients 
from the study group (41 of them positive for JCV DNA); and b) dysplastic/neoplastic colorectal 
lesions consisting in 60 adenomas (55 of them positive for JCV DNA) and 14 adenocarcinomas (12 of 
them positive for JCV DNA) from patients of the study group (Chapter 2). 
 
 
 
 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
77 
 
3.3.2. Mutational Analysis of the p53 gene 
3.3.2.1. PCR Amplification of TP53 exons 
In order to amplify TP53 exons, we designed several pairs of TP53-specific exon primers 
(forward and reverse), targeted to exons 1 to 11 (prepared by StabVida, Caparica, Portugal) (Table 
3.1). PCR primers anneal to the intron sequences, immediately upstream and downstream of each 
exon, and enclosed fragments with sizes ranging from 186-500b.p. As most inactivating genetic 
alterations occur within the DNA binding domain (codons 102-292), and considering that this is the 
interaction domain with JCV T-Ag, we focused our attention to the exons encoding this region of the 
protein, which comprises exons 5 through 8. 
The PCR reaction, for the amplification of each TP53 exon, was carried out individually in a 
PCR mixture of 50µl of final volume containing 1× PCR incomplete buffer (50mM KCl/10mM Tris 
HCl/2mM) (Bioron, Ludwigshafen, Germany), 2mM of Mg2+ (Bioron, Ludwigshafen, Germany), 
200µM of dNTPs (Bioron, Ludwigshafen, Germany), 20pmol of each primer (forward and reverse), 
2.5units of Taq DNA polymerase (Bioron, Ludwigshafen, Germany), 50ng of DNA obtained from 
each normal colorectal mucosa sample and Mili-Q water until complete the final volume. The 
reactions were then submitted to thermal cycling: a Hot-Start (96oC for 1’), followed by 40 cycles of 
denaturing at 96ºC for 1’, annealing at 60ºC for 30’’ and extension at 72ºC for 1’, with a final 
extension step at 72ºC for 10’. 
All PCR’s included a “no template” control (with no target DNA added), to ensure that our 
solutions were not contaminated with other DNA that might serve as a template. 
The success of the PCR amplification was confirmed by horizontal electrophoresis on agarose 
gels, as previously described in Chapter 2. TP53 amplimers were identified by comparison with the 
fragments of a known molecular weight marker, 100b.p. ladder (Bioron, Ludwigshafen, Germany). 
Finally, all the PCR products were purified with ExoSAP®-IT For PCR Product Clean-Up Kit, 
according to manufacturer’s instructions, aiming to remove single-stranded DNA (i.e., primers and 
incomplete PCR products) and unconsumed dNTPs. 
 
3.3.2.2. TP53 Sequencing 
Before sequencing, the templates were treated with BigDye® Terminator Ready Reaction Mix 
v3.1 (Applied Biosystems, Germany), according to manufacturer’s protocol for short templates, as 
those obtained from the PCR amplification using our TP53- specific exon primers (<500b.p.). Then, 
each sequencing PCR reaction was prepared individually, for a final volume of 20µl, and contained 5x 
Buffer (Applied Biosystems, Germany), 2.5ng of the primer (forward or reverse), 4µl of the treated 
template and Mili-Q water to complete the final volume. The reactions were then submitted to 25 
thermal cycles of 96ºC for 10’’, 50ºC for 5’’ and 60ºC for 4’. These sequencing PCR products were 
cleaned-up with Sefadex® resin and centrifuged at 2000rpm (1539g) for 1’. 
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Finally, all templates were sequenced in an Applied Biosystems® 3130 Genetic Analyser 
(Applied Biosystems, Germany), in both directions (with forward and reverse primers) to avoid 
ambiguities. 
 
3.4. Results 
3.4.1. TP53 genetic alterations in normal colorectal mucosa from infected and non-infected 
individuals 
In a total of 81 normal colorectal mucosa specimens infected by JC virus, from 40 controls and 
41 patients, the mutational analysis of the TP53 gene by DNA Direct Sequencing allowed the 
detection of several genetic alterations in 10 of the 40 controls (25%) and 30 of the 41 patients(73%). 
Furthermore, from the 119 normal colorectal mucosa samples with no positivity for JCV DNA (60 
controls and 59 patients) we were able to identify a single TP53 defect in 5 of the 60 controls (8%) and 
13 of the 59 patients (22%). 
 
Our study revealed several variants of the TP53 gene: a) three intronic single nucleotide 
polymorphisms (SNPs) in intron 2 – an homozygous C insertion at position 11818 (Figure 3.1A), an 
G>C substitution at position 11827 (Figure 3.1B) and an homozygous C insertion at position 11875 
(Figure 3.1C); b) a synonymous A>G substitution at position 13399 in the exon 6 (Figure 3.1D); and 
c) a new homozygous C insertion at position 19037 in the 3’UTR (3’ untranslated region) of the exon 
11 (not described to date), exclusively found in the normal colorectal mucosa of 10 JCV infected 
patients (Figure 3.1E). The C insertion at position 11875 in intron 2 was the only variant identified in 
individuals with no positivity for JC virus. No other genetic alterations were detected in TP53 gene, 
even within the DNA binding domain, which comprises exons 5 through 8 and where interaction with 
JCV T-Ag occurs. 
 
The absolute frequencies of these TP53 variants, identified in the normal colorectal mucosa of 
JCV infected and non-infected individuals, are presented in Table 3.2A, as well as the allelic and 
genotypic frequencies in Table 3.2B. 
 
3.4.2. TP53 mutational status in adenomas and adenocarcinomas from JCV infected versus non-
infected patients 
From a total of 74 dysplastic/neoplastic colorectal lesions, 60 adenomas (55 JCV+ and 5 JCV-) 
and 14 adenocarcinomas(12 JCV+ and 2 JCV-) from patients included in the study group, the 
mutational analysis of the TP53 gene allowed the detection of genetic alterations in all the studied 
samples. 
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We were able to identify four concomitant TP53 genetic alterations: a) the G>C substitution at 
position 11827 in the intron 2(Figure 3.2A); b) a C>G substitution at position 12139 in the exon 4 
(Figure 3.2B); c) the synonymous A>G substitution at position 13399 in the exon 6 (Figure 3.2C); and 
d) the new homozygous C insertion at position 19037 in the 3’UTR of the exon 11 (Figure 3.2D). 
Again, the TP53 3’UTR variant was exclusively detected in colorectal lesions from 62 patients with 
positivity for the presence of JC virus DNA. No other genetic alterations were detected in TP53 gene. 
 
The absolute frequencies of TP53 variants detected in the dysplastic/neoplastic colorectal 
mucosa of the JCV infected and non-infected patients from the study group are listed in Table 3.3A 
and the allelic and genotypic frequencies in Table 3.3B. 
 
3.5. Discussion 
Concerning to TP53 mutational analysis reports state that more than 90% of the mutations 
reported in p53 gene are clustered between exons 4 and 8. This region is highly conserved throughout 
evolution and contains the DNA-binding domain of p53, which is essential for its activity. This 
contrasts with the trans-activation domain (encoded by exons 2 and 3) and the regulatory region 
(encoded by exons 9 to 11), where few mutations have been described[22]. 
The new TP53 single nucleotide polymorphisms identified in our experimental approach, a 
homozygous C insertion at position 1903 in the 3’ UTR of exon 11 (19037insC Ex11), revealed to be 
a significantly recurrent and exclusive characteristic of the colorectal mucosa, either normal or 
dysplastic/neoplastic, of the JCV infected individuals with clinical history of colorectal lesions, when 
comparing with controls and non-infected patients. 
Bibliographic reports state that the cis-regulatory elements in the 3’-UTRs play an important 
role in the translation, localization and stability of the mRNA and genetic alterations within this region 
can be the cause of several diseases, such as congenital heart disease (CHD), associated with 3’-UTR 
variations in GATA4 gene[23], and arrhythmogenic right ventricular cardiomyopathy/dysplasia 
(AVRC), also invariably related with abnormal TGF-beta3 3’-UTR[24]. 
The research on the pathophysiology of diseases and mutations affecting the functionality of 
the 3’-UTR is still sparse. However, the available data do suggest that this mRNA region, which is 
often neglected during the genetic screening of disease-associated candidate genes, plays an important 
role in various diseases and disease progression[25,26]. 
The 3’-UTR is characterized by secondary structures which play an important role in the 
interaction of mRNAs with the associated proteins. A disturbance in these structures, due to inherent 
genetic changes in sequence, alters its interaction with other proteins. A study by Chen et al[27] on 
eighty three disease-associated variants in the 3’-UTR of various human mRNAs revealed a 
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correlation between the functionality of these variants and alterations in the predicted secondary 
structure. Such studies emphasize the importance of this region in translational regulation. 
Using a prediction bioinformatic tool (3D-JIGSAW Protein Comparative Modelling Server – 
Cancer Research UK) for a secondary structure preview of the TP53 3’-UTR, both for wild-type and 
mutant 19037insC sequences, we found significant differences between the predictive secondary 
structures, probably due to the considerable changes in codon frame. Since mutations affecting the 
secondary structure of 3’-UTR of mRNA can cause translation deregulation and diseases, we may 
presume that the 19037insC in the 3’ UTR of TP53 gene may be related in some extend with a 
predisposition to a p53/JCV T-Ag-mediated colorectal carcinogenesis, and act as a risk modifier in 
JCV infected individuals. In fact, all the available information suggest a direct association between the 
mutations in 3’-UTR and disease development. However, this possibility needs further confirmation. 
 
Although located in a non-coding region, one might consider that the three intronic single 
nucleotide polymorphisms found in TP53 intron 2 can become noticed in p53 protein function. 
Perhaps changes in the nucleotide sequence of the genome of p53 can altered the splicing signals 
required for appropriate splicing of p53 and caused more severe genetic alterations. In fact, the C 
insertions found at positions 11818 and 11875 of TP53 intron 2 (11818insC Int2 and 11875insC Int2), 
were previously described by Soto et al[22] as involved in melanoma tumourigenesis. The G to C 
transversion found at position 11827 in TP53 intron 2 (11827G>C Int2), at b.p. +38 following the 
splice donor site of exon 2, was also already described by Pleasants et al[28] and Oliva et al[29] as a 
polymorphic site useful as a marker to detect the loss of heterozygosity in human tumours, such as soft 
tissue sarcomas, bladder carcinomas and colorectal carcinoma. Despite the 11827G> C Int2 variant 
has been detected in the normal mucosa of individuals from the control group, positive for the 
presence of JC virus DNA, its relative frequency is not representative. 
 
Concerning to the synonymous A>G substitution at position 13399 in the exon 6 (13399A>G 
Ex6), a silent variant at codon 213 (CGA to CGG) that codes the aminoacid arginine, although located 
within p53 interaction domain with JCV T-antigen, is clear that nucleotide change does not alter the 
aminoacid transcript and, consequently, no changes shall occur in the p53 structure and affinity to JCV 
T-Ag [30]. 
 
The C>G substitution at position 12139 in the exon 4 (12139C>G Ex4) is described as a 
missense genetic alteration at codon 72 (CCC to CGC) which promotes the change from the 
aminoacid proline (variant p53-P72) to arginine (variant p53-R72). The p53-P72 variant has been 
reported as the ancestral form, although the p53-R72 may occur at a high frequency (>50%) in some 
populations[31,32]. 
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The codon 72 in TP53 exon 4 is located within the gene segment that encodes the polyproline 
domain, which lies between the N-terminal transactivating domain and the DNA-binding domain, in 
which most tumour-associated mutations are found. The precise contribution of the polyproline 
domain to p53 regulation and function is still unclear. Unlike the DNA-binding domain, the 
polyproline domain is less well-conserved across species than the DNA-binding domain and is not a 
common location of tumour-associated mutations. Deletion studies in cells and mice support the view 
that the polyproline domain is essential for p53 to mount a full apoptotic response to stress and inhibit 
tumourigenesis[33,34,35,36]. 
A decade ago, a dramatic effect of the p53 codon 72 variant on the risk of cervical cancer was 
reported. This effect was explained by the finding that the E6 oncoprotein from high-risk mucosal 
Human Papillomaviruses (HPVs) causes more efficient degradation of p53-R72 than p53-P72, 
reducing cellular levels of p53 and increasing the risk of HPV-associated cancers in p53-R72 
homozygotes[37]. These findings triggered an intensive investigation on the potential effect of the p53 
codon 72 polymorphism on susceptibility to various cancers or cancer-related phenotypes that is still 
ongoing. Interestingly, our results suggest that the codon 72 variant of TP53 gene may be associated 
with sporadic colorectal adenoma/adenocarcinoma risk in carriers of the Arginine/Arginine genotype. 
In fact, it remains plausible that the codon 72 variant is a modifier of cancer risk or age of onset when 
considered in the context of other genetic and cancer-associated mutations in other genes [38,39,40]. 
Recently, Vilkin and colleagues[41] tried to clarify the role of JCV in tumour development in 
patients with sporadic colorectal cancer and with positive family history and Bethesda criteria. They 
were unable to conclude that, on a background of genetic mutations in mismatch repair genes, JCV 
acts as an additional event leading to CRC, but yet CRC patients with positive family history have a 
higher incidence of JCV T-Ag. This suggests a potential collaboration between some predisposition 
genes and JCV. Our finding of some p53 intronic nucleotide changes detected more frequently in 
colorectal lesions, but also present in controls, is consistent with this interpretation. In colorectal 
cancer p53 mutations are frequent at late stages of tumour development. 
Thus, our finding that no p53 mutations were detected in mostly early lesions is consistent 
with this late role. However, it is interesting to note that most p53 nucleotide alterations were 
identified within intron 2, and were also present in the normal population. These are likely 
polymorphisms that indirectly might facilitate, or contribute to, transformation of JCV-infected normal 
cells. A similar role might be played by the new and common mutation identified only in adenoma or 
carcinoma cases that is located within the 3’ un-translated region. One common mechanistic aspect to 
all these different nucleotide changes in non-coding regions is that they might affect RNA stability, 
leading to a lower level of p53 protein and somehow making p53-mediated responses less efficient, 
and in that way predisposing to tumour initiation or progression. 
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3.6. Conclusions 
It is generally accepted that the inactivation of the tumour suppressor gene TP53, caused by 
genetic variations, is a common event in the genesis of several human tumours. As previously reported 
in several studies, the occurrence of intronic genetic alterations in the p53 genome may result in an 
alternative pattern of splicing leading to the generation of a p53 variant which encompasses the T-
antigen binding site. It is proved that variations in the close proximity of or within the T-antigen 
binding site may affect proper folding of the p53 protein and its binding to JCV T-antigen. 
 
Our experimental approach revealed that the most relevant genetic alterations found in TP53 
gene, such as the new SNP identified in TP53 3’ UTR (19037insC Ex11) and the TP53 codon 72 
variant (12139C>G Ex4), seem to be a common and exclusive characteristic of the colorectal 
epithelium cells of JCV infected individuals, especially those with clinical history of colorectal 
lesions. The TP53-3’ UTR variant, with its contribution to changes in the secondary structure of the 
3’-UTR, may be associated, in some extent, with a p53/JCV T-Ag-mediated colorectal carcinogenesis 
in JCV infected individuals. Additionally, our results suggest that the codon 72 variant of TP53 gene 
may be associated with a sporadic colorectal adenoma/adenocarcinoma risk in carriers of the 
Arginine/Arginine genotype. In fact, it is believed that the codon 72 variant is a modifier of cancer risk 
or age of onset when considered in the context of other genetic and cancer-associated mutations in 
other genes. 
We may suggest that these p53 variants may, probably, participate as risk modifiers in the 
JCV-mediated colorectal cancer development, but still, the implication of such variants in this context 
requires further elucidation. 
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3.9. Figures and Tables 
 
b.p.=Base Pairs 
F=Forward 
R=Reverse 
TABLE 3.1. Oligonucleotide sequences for mutational screening of TP53 gene by PCR-DNA sequencing. 
Gene Target DNA Sequence Primer Name Primer Sequence 
TP53 
Exon 1 
(186b.p.) 
P53E1F 5´-gctcaagactggcgctaaaa-3’ 
P53E1R 5´-gtgactcagagaggactcat-3’ 
Exons 2 and 3 
(352b.p.) 
P53E2/3F 5’-aagtgtctcatgctggatcc-3’ 
P53E2/3R 5’-aaagagcagtcagaggacca-3’ 
Exon 4 
(351b.p.) 
P53E4F 5’-tggtcctctgactgctcttt-3’ 
P53E4R 5’-tgaagtctcatggaagccag-3’ 
Exons 5 and 6 
(487b.p.) 
P53E5/6F 5’-cacttgtgccctgactttca-3’ 
P53E5/6R 5’-ccactgacaaccacccttaa-3’ 
Exon 7 
(351b.p.) 
P53E7F 5’-cttgcagtgagctgagatca-3’ 
P53E7R 5’-agaaatcggtaagaggtggg-3’ 
Exons 8 and 9 
(417b.p.) 
P53E8/9F 5’-taaatgggacaggtaggacc-3’ 
P53E8/9R 5’-tccacttgataagaggtccc-3’ 
Exon 10 
(232b.p.) 
P53E10F 5’-gagtgagaccccatctcaaa-3’ 
P53E10R 5’-tttccaacctaggaaggcag-3’ 
Exon 11 
(500/471/499b.p.) 
P53E11F1 5’-gaccctctcactcatgtgat-3’ 
P53E11R1 5’-gcatttcacagatatgggcc-3’ 
P53E11F2 5’-gaagctgtccctcatgttga-3’ 
P53E11R2 5’-aaagcgagacccagtctcaa-3’ 
P53E11F3 5’-ctggatccaccaagacttgt-3’ 
P53E11R3 5’-tccacactcattgcagactc-3’ 
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Figure 3.1 
Diagrams of DNA sequencing electrophoresis showing TP53 genetic variants found in the normal colorectal mucosa from 
patients and controls infected and non-infected by JC virus. 
A=Adenine; T=Thymine; C=Cytosine; G=Guanine; R=A/G 
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TABLE 3.2A. Absolute frequencies of TP53 variants in the normal colorectal mucosa of JCV infected and 
non-infected individuals from both control and study groups. 
 Absolute Frequencies 
Control Group (n=100) Study Group (n=100) 
TP53 Genetic Variants JCV+ (n=40) JCV- (n=60) JCV+ (n=41) JCV- (n=59) 
11818insC Int2 1 0 3 0 
11827G>C Int2 3 0 5 0 
11875insC Int2 1 5 1 13 
13399A>G Ex6 5 0 11 0 
19037insC Ex11 (new) 0 0 10 0 
TOTAL n=10 n=5 n=30 n=13 
 
TABLE 3.2B. Allelic and genotypic frequencies of TP53 variants in the normal colorectal mucosa of JCV 
infected individuals from both control and study groups. 
TP53 Genetic Variants Control Group JCV+ (n=40) Study Group JCV+ (n=41) 
 
11827G>C Int2 
Allelic* Genotypic** Allelic* Genotypic** 
G – 0.96 
C – 0.04 
GG – 0.925 
GC – 0.075 
CC – 0 
G – 0.89 
C – 0.11 
GG – 0.878 
GC – 0.024 
CC – 0.098 
n=3 n=5 
 
13399A>G Ex6 
Allelic* Genotypic** Allelic* Genotypic** 
A – 0.94 
G – 0.06 
AA – 0.875 
AG – 0.125 
GG - 0 
A – 0.76 
G – 0.24 
AA – 0.731 
AG – 0.048 
GG – 0.221 
n=5 n=11 
JCV+=Positive for JCV DNA 
JCV-=Negative for JCV DNA 
*Allelic Frequency: 
f(B) = ((2xnumber of homozygous BB) + (number of heterozygous Bb))/(2xtotal of individuals) 
f(b) = ((2xnumber of homozygous bb) + (number of heterozygous Bb))/(2xtotal of individuals) 
f(B)+f(b)=1 
**Genotypic Frequency: 
f(BB) = number of homozygous BB/total of individuals 
f(Bb) = number of heterozygous Bb/total of individuals 
f(bb) = number of homozygous bb/total of individuals  
f(BB)+f(Bb)+f(bb)=1 
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Figure 3.2 
Diagrams of DNA sequencing electrophoresis showing the TP53 genetic alterations found in colorectal adenomas and 
adenocarcinomas from JCV infected and non-infected patients. 
A=Adenine; T=Thymine; C=Cytosine; G=Guanine; S=G/C; R=A/G 
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TABLE 3.3A. Absolute frequencies of TP53 variants in adenomas and adenocarcinomas from JCV infected and non-
infected patients from the study group. 
 Absolute Frequencies 
 Adenomas (n=60) Adenocarcinomas (n=14) 
TP53 Genetic Variants JCV+ (n=55) JCV- (n=5) JCV+ (n=12) JCV- (n=2) 
11827G>C Int2 21 0 10 0 
12139C>G Ex4 38 0 12 0 
13399A>G Ex6 49 5 11 2 
19037insC Ex11 (new) 55 0 12 0 
TOTAL n=55 n=5 n=12 n=2 
 
TABLE 3.3B. Allelic and genotypic frequencies of TP53 variants in adenomas and adenocarcinomas of JCV infected patients from the 
study group. 
TP53 Genetic Variants Adenomas (n=60) Adenocarcinomas (n=14) 
 
 
 
11827G>C Int2 
Allelic* Genotypic** Allelic* Genotypic** 
JCV+ (n=55) JCV+ (n=55) JCV+ (n=12) JCV+ (n=12) 
G-0.69 
C-0.31 
GG-0.618 
GC-0.146 
CC-0.236 
G-0.21 
C-0.79 
GG-0.166 
GC-0.084 
CC-0.750 
n=21 n=10 
 
 
 
12139C>G Ex4 
Allelic* Genotypic** Allelic* Genotypic** 
JCV+ (n=55) JCV+ (n=55) JCV+ (n=12) JCV+ (n=12) 
C-0.49 
G-0.51 
CC-0.309 
CG-0.364 
GG-0.327 
C-0.04 
G-0.96 
CC-0 
CG-0.083 
GG-0.917 
n=38 n=12 
 
 
 
13399A>G Ex6 
Allelic* Genotypic** Allelic* Genotypic** 
JCV+ 
(n=55) 
JCV- 
(n=5) 
JCV+ 
(n=55) 
JCV- 
(n=5) 
JCV+ 
(n=12) 
JCV- 
(n=2) 
JCV+ 
(n=12) 
JCV- 
(n=2) 
A-0.21 
G-0.79 
A-0.20 
G-0.80 
AA-0.109 
AG-0.200 
GG-0.691 
AA-0 
AG-0.400 
GG-0.600 
A-0.13 
G-0.87 
A-0.50 
G-0.50 
AA-0.083 
AG-0.083 
GG-0.834 
AA-0 
AG-1 
GG-0 
n=49 n=5 n=49 n=5 n=11 n=2 n=11 n=2 
JCV+=Positive for JCV DNA 
JCV-=Negative for JCV DNA 
*Allelic Frequency: 
f(B) = ((2xnumber of homozygous BB) + (number of heterozygous Bb))/(2xtotal of individuals) 
f(b) = ((2xnumber of homozygous bb) + (number of heterozygous Bb))/(2xtotal of individuals) 
f(B)+f(b)=1 
**Genotypic Frequency: 
f(BB) = number of homozygous BB/total of individuals 
f(Bb) = number of heterozygous Bb/total of individuals 
f(bb) = number of homozygous bb/total of individuals  
f(BB)+f(Bb)+f(bb)=1 
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CHAPTER 4 
 
4. Final Considerations 
4.1. Overall Findings 
JC polyomavirus (JCV) is a significant human pathogen with an intricate biology. However, a 
causative role for JCV in human cancers has not yet been established. What criteria are necessary to 
establish causality or an association of JCV with human cancers? Some of the necessary criteria to 
establish a causal relationship between a virus and cancer include the detection of viral genome or 
gene products in cancer tissue, a molecular basis for virus-induced oncogenicity and consistency of the 
association. 
Does JCV fit these criteria? In addition to the evidence that JCV can cause tumours in 
experimental animals and transform cells in culture, the viral genomic DNA and the expression of the 
viral proteins has been demonstrated in several tumour tissues. The oncogenic properties of JCV are 
well described in the literature and attributed to its oncoprotein, the large T-antigen (T-Ag), which 
directly interacts with tumour suppressor proteins and cell-cycle regulators to disrupt the cell cycle and 
prevent apoptosis. Laboratory studies of this viral protein have demonstrated that T-Ag has the ability 
to immortalize cells in culture and its expression in transgenic mice results in the development of 
tissue-specific tumours. However, a reliable association of JCV with a particular type of tumour or 
human cancer has not been consistently established. In fact, JCV has been reported to contribute to a 
wide variety of tumours indicating that there is not a clear correlation of JCV with a particular type of 
cancer.  
 
The design of the present study was based in the fact that there are relatively few reports that 
implicate JCV in human cancers, a comparable number of studies that refute these findings and a lack 
of epidemiological studies that, specifically, link JCV to human colorectal cancer (CRC). Still, we 
found reasonable to hypothesize that JCV may act as a co-factor in human colorectal tumourigenesis. 
 
The results of our study allowed us to consider that the presence of JCV DNA in colorectal 
lesions is an early and sustained event during tumour progression, unrelated with the lesion type, grade 
or severity, and that JCV may have a specific tropism for CRC and colorectal polyps, either 
hyperplastic or dysplastic (adenomas). This observation may reflect a condition where the transformed 
colorectal epithelial cells offer a more permissive environment for viral replication, being effective 
even since the hyperplastic polyps not prone to carcinogenesis. In fact, all together, our findings 
suggest that JC polyomavirus infection may precede the colorectal lesion occurrence, probably acting 
as a risk co-factor, or just be related with its progression, acting as a carcinogenic enhancer. 
 
Assessment of JC polyomavirus in normal colorectal mucosa, hyperplastic polyps and sporadic adenomas 
and adenocarcinomas in a Portuguese population and its association with cancer development 
2013 
 
 
98 
 
Furthermore, we propose the epidemiological extent of the JCV infection in the 
gastrointestinal and urinary tracts of the normal Portuguese population, and the occurrence of a 
biological selection of JCV infected cells during tumourigenesis in individuals with colorectal lesions. 
 
Additionally, our experimental approach revealed that the most relevant genetic alterations 
found in TP53 gene, such as the new single nucleotide polymorphism identified in TP53 3’-
untranslated region (19037insC Ex11) and the TP53 codon 72 variant (12139C>G Ex4), seems to be a 
common and exclusive characteristic of the colorectal epithelium cells of JCV infected individuals, 
especially those with clinical history of colorectal lesions. These p53 variants can participate, in some 
extent, as risk modifiers in JCV-mediated colorectal cancer development. Still, the implication of such 
variants in the context of the JCV-mediated colorectal carcinogenesis requires further elucidation. 
On the other hand, finding that no p53 mutations were detected in mostly early lesions is 
consistent with the late role of the p53 protein in colorectal carcinogenesis, which, at the same time, 
suggests an early role for JCV contribution to this type of tumour. However, it is interesting to note 
that most p53 nucleotide alterations are identified within intron 2 and are also present in JCV-infected 
controls. These polymorphisms are likely to indirectly facilitate, or contribute to, the transformation of 
JCV-infected normal cells. A similar role might be played by the new and common mutation, located 
within the 3’-untranslated region and identified only in adenomas and adenocarcinoma of JCV 
infected patients. 
One common mechanistic aspect to all of these different nucleotide changes in non-coding 
regions is that they might affect RNA stability or result in RNA-mediated decay. The net effect would 
probably be a reduced level of cellular p53 protein, making, somehow, p53-mediated responses less 
efficient and predisposing to tumour initiation or progression. 
 
These associations may be too speculative considering that no other evidences has been 
reported or studied yet. In fact, we do not know if these p53 variants, present in colorectal epithelium 
cells, are restricted to the Portuguese or Iberian populations or if its presence is more widespread, 
being possible to detect it in other populations. If so, it has not been reported or given any attention by 
itself or in the context of colorectal cancer. 
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4.2. General Considerations 
The recent identification of many components of the Polyomaviridae family that are able to 
infect humans represents a strong incentive for the scientific community to improve and increase the 
research on the oncogenic potentialities of these viruses. The ubiquity and persistent nature of 
polyomaviruses make them very challenging in order to define the mechanisms of their pathogenicity. 
In particular, since the association between the viral aetiology of the tumours and the state of the host 
immune system is well established, it is urgent to focus future studies on the nature of the relationship 
between the host immune system and polyomaviruses infection. 
JCV reactivation in non-permissive cells after treatment with immuno-modulatory therapies, 
such as colorectal epithelial cells in Crohn’s disease patients, in association with other host tumour-
inducing factors, could provide valid information on the role of JCV in several malignancies, such as 
colorectal cancer. 
Studies analyzing the association of JCV with human tumours in various states of immuno-
competency would be worthwhile and may reveal interesting new insights into the role of JCV in 
human cancers. On the other hand, the inflammatory infiltration caused by the local JCV chronic 
infection of the colorectal mucosa can contribute, itself, to the selection and expansion of tumour-
prone cells. This is an issue that has not been explored in the context of gastrointestinal JCV infection 
and which deserves further attention, particularly if considering that chronic inflammation is a risk 
factor in colorectal cancer. 
 
The inactivation of the tumour suppressor gene TP53 caused by genetic variations is a 
common event in the genesis of several human tumours. As previously reported in several studies, the 
occurrence of intronic genetic alterations in the p53 genome may result in an alternative pattern of 
splicing, leading to the formation of p53 variants which encompasses the T-Ag binding site. It is 
proved that variations in the close proximity of or within the T-Ag binding site may affect proper 
folding of the p53 protein and its binding to JCV T-Ag. 
 
To our knowledge, it is appropriate to consider that JCV can initially infect uncontrolled 
dividing tumour cells and then the expression of viral early genes may contribute to oncogenesis. It is 
known that CRC originates in epithelial cells which replicates at a relatively high rate, with 1010 
epithelial cells being replaced every day. This high rate of replication is thought to contribute to the 
vulnerability of colon epithelium to mutation and consequent carcinogenesis. If colonic epithelial cells 
accumulate mutations in oncogenes and tumour suppressor genes, the morphology of the cell changes, 
and there is a hyper-proliferation of the abnormal ones. If JCV infection occurs in a cell that is already 
undergoing aberrant cell growth, due to misregulation of the cell cycle or other genetic or 
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environmental predisposition factors, JCV may provide the “second hit” that prompt to cancer 
development. 
Therefore, it is worthwhile to carry-out gene expression assays in order to demonstrate the 
differences between normal and tumoural colorectal tissue or to clarify the interaction between p53 
protein and JC polyomavirus. Is doubtless crucial to continue exploring the role of JCV in human 
cancers as a co-factor in oncogenesis, especially since ever-changing environmental and social factors 
play such an important role in disease pathogenesis and cancer. 
 
In order to properly establish if JCV is indeed an important risk co-factor in colorectal cancer 
there are several issues that need to be properly addressed: a) establish conclusively that CRC patients, 
in a significant number of cases, have been exposed to this virus, and that an indirect marker will be 
the presence of specific antibodies; b) improve detection of viral DNA, by using standardized sets of 
primers for each of the relevant viral genes, as well as strain identification; this should also contribute 
to establish the potential and irreversible integration of remnant JCV DNA in cancer cells, and permit 
identification of significant differences among malignant, benign or normal surrounding tissue; c) 
correlate JCV DNA presence with other mutations known to sequentially occur in CRC, and its 
association with other known risk factors; d) identify the viral protein expression at different stages of 
colorectal cancer progression; for this purpose, the development of more specific antibodies for JCV 
proteins are necessary; and e) characterize the host immune response to JCV in order to manipulate it 
and develop strategies to eradicate the virus from the human population, particularly to determine the 
role T-cell responses, since the natural antibody response does not seem to be protective. 
 
We consider that future studies need to establish a standard, reliable, and reproducible test for 
the detection of JC virus DNA. This test should be evaluated in masked specimens, multiple 
populations and different laboratories to insure the validity of the results. In addition, prospective 
studies of faecal carriage of JC virus in relation to colorectal cancer are absent from the literature. 
Such studies could help to determine the specificity, and possibly the causality, of the association 
between JC virus and colorectal cancer, and if faecal carriage of virulent JCV subtypes occurs prior to 
the development of colorectal neoplasia and at higher rates in cases than in controls. 
 
Finally, we consider that the short-term planning of strategies to reduce the burden of JCV in 
the population might contribute to reduce the incidence of colorectal cancer, similarly to other human 
cancer associated to infectious agents. In addition, the local inflammatory reaction in response to 
chronic infection, even if mild, might also be an important factor to facilitate tumour development and 
it can also be a target in order to reduce its risk. 
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